Biomarkers For Pre-selection Of Patients For Anti-igf1r Therapy

  *US07811562B2*
  US007811562B2                                 
(12)United States Patent(10)Patent No.: US 7,811,562 B2
 Wang et al. (45) Date of Patent:Oct.  12, 2010

(54)Biomarkers for pre-selection of patients for anti-IGF1R therapy 
    
(75)Inventors: Yan Wang,  Scotch Plains, NJ (US); 
  Jonathan A. Pachter,  Setauket, NY (US); 
  Yaolin Wang,  Edison, NJ (US); 
  Ming Liu,  Fanwood, NJ (US) 
(73)Assignee:Schering Corporation,  Kenilworth, NJ (US), Type: US Company 
(*)Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. 
(21)Appl. No.: 11/290,687 
(22)Filed: Nov.  30, 2005 
(65)Prior Publication Data 
 US 2006/0140960 A1 Jun.  29, 2006 
 Related U.S. Patent Documents 
(60)Provisional application No. 60/633,156, filed on Dec.  3, 2004.
 
(51)Int. Cl. A61K 039/395 (20060101)
(52)U.S. Cl. 424/133.1; 424/155.1
(58)Field of Search  424/133.1, 155.1

 
(56)References Cited
 
 U.S. PATENT DOCUMENTS
 4,543,439  A  9/1985    Frackelton, Jr. et al.     
 5,198,340  A  3/1993    Mukku     
 5,262,308  A  11/1993    Baserga     
 5,942,412  A  8/1999    Prager et al.     
 5,958,872  A  9/1999    O'Connor et al.     
 5,977,307  A  11/1999    Friden et al.     
 6,022,711  A  2/2000    Cunningham et al.     
 6,084,085  A  7/2000    Baserga et al.     
 6,294,330  B1  9/2001    Michnick et al.     
 6,300,129  B1  10/2001    Lonberg et al.     
 6,316,462  B1  11/2001    Bishop et al.     
 6,333,031  B1  12/2001    Olsson et al.     
 6,346,390  B1  2/2002    Olsson et al.     
 6,372,250  B1  4/2002    Pardridge     
 6,537,988  B2  3/2003    Lee     
 6,645,775  B1  11/2003    Clark et al.     
 7,037,498  B2  5/2006    Cohen et al.     
 7,217,796  B2  5/2007    Wang et al.     
 7,326,567  B2  2/2008    Saha     
 2002//0022023  A1  2/2002    Ullrich et al.     
 2002//0025313  A1  2/2002    Micklus et al.     
 2002//0107187  A1  8/2002    Kingston et al.     
 2002//0132275  A1  9/2002    Fidler et al.     
 2002//0155095  A1  10/2002    Nagabhushan et al.     
 2002//0164333  A1  11/2002    Nemerow et al.     
 2002//0169116  A1  11/2002    Kingston et al.     
 2002//0187925  A1  12/2002    Kingston et al.     
 2002//0197262  A1  12/2002    Hasan et al.     
 2003//0021780  A1  1/2003    Smith et al.     
 2003//0031658  A1  2/2003    Brodt et al.     
 2003//0045676  A1  3/2003    Kingston et al.     
 2003//0087342  A1  5/2003    Mermod et al.     
 2003//0088061  A1  5/2003    Staunton     
 2003//0092631  A1  5/2003    Deshayes et al.     
 2003//0138430  A1  7/2003    Stimmel et al.     
 2003//0165502  A1  9/2003    Fujita-Yamaguchi     
 2003//0195147  A1  10/2003    Pillutla et al.     
 2003//0235582  A1  12/2003    Singh et al.     
 2003//0236190  A1  12/2003    Pillutla et al.     
 2004//0009154  A1  1/2004    Khan et al.     
 2004//0009906  A1  1/2004    Kakkis et al.     
 2004//0018191  A1*1/2004    Wang et al. 424/143.1
 2004//0023887  A1  2/2004    Pillutla et al.     
 2004//0047835  A1  3/2004    Bianco     
 2004//0057950  A1  3/2004    Waksal et al.     
 2004//0086503  A1  5/2004    Cohen et al.     
 2004//0086511  A1  5/2004    Zack et al.     
 2004//0102360  A1  5/2004    Barnett et al.     
 2004//0116330  A1  6/2004    Naito et al.     
 2004//0142381  A1  7/2004    Hubbard et al.     
 2004//0202651  A1*10/2004    Cohen et al. 424/131.1
 2004//0228859  A1  11/2004    Graus et al.     
 2004//0265307  A1  12/2004    Singh et al.     
 2005//0008642  A1  1/2005    Graus et al.     
 2005//0048050  A1  3/2005    Fujita-Yamaguchi     
 2005//0069539  A1  3/2005    Cohen et al.     
 2005//0081812  A1  4/2005    Toedter et al.     
 2005//0084906  A1  4/2005    Goetsch et al.     
 2005//0136063  A1*6/2005    Wang et al. 424/178.1
 2005//0176099  A1  8/2005    Saha     
 2005//0186203  A1  8/2005    Singh et al.     
 2005//0244408  A1  11/2005    Cohen et al.     
 2005//0249728  A1  11/2005    Singh et al.     
 2005//0249730  A1  11/2005    Goetsch et al.     
 2005//0272637  A1  12/2005    Clinton et al.     
 2005//0272755  A1  12/2005    Denis et al.     
 2005//0281812  A1  12/2005    Cohen et al.     
 2006//0018910  A1  1/2006    Gualberto et al.     
 2006//0205810  A1  9/2006    Zong et al.     
 2006//0233810  A1*10/2006    Wang et al. 424/155.1
 2006//0233814  A1  10/2006    Goldmakher et al.     
 2006//0286103  A1  12/2006    Kolhe et al.     
 2007//0059241  A1*3/2007    Wang et al. 424/1.49
 2007//0059305  A1*3/2007    Wang et al. 424/143.1
 2007//0071675  A1  3/2007    Wu et al.     
 2008//0014197  A1  1/2008    Wang et al.     
 2008//0112888  A1  5/2008    Wang     

 
 FOREIGN PATENT DOCUMENTS 
 
       DE       197 19 001       C2                5/2001      
       FR       2 834 900                         7/2003      
       FR       2 834 990                         7/2003      
       FR       2 834 991                         7/2003      
       WO       WO 91/04014                         4/1991      
       WO       WO 91/14438                         10/1991      
       WO       WO 97/44352                         11/1997      
       WO       WO98/17801                         4/1998      
       WO       WO 98/22092                         5/1998      
       WO       WO 98/45427                         10/1998      
       WO       WO 99/25378                         5/1999      
       WO       WO 99/28347                         6/1999      
       WO       WO 99/42127                         8/1999      
       WO       WO 99/60023                         11/1999      
       WO       WO 00/22130                         4/2000      
       WO       WO 00/50067                         8/2000      
       WO       WO 00/69454                         11/2000      
       WO       WO 01/07084       A1                2/2001      
       WO       WO 01/30964       A2                5/2001      
       WO       WO 01/36632       A3                5/2001      
       WO       WO 01/70268       A1                9/2001      
       WO       WO 01/70930       A2                9/2001      
       WO       WO 01/72771       A2                10/2001      
       WO       WO 01/75064       A2                10/2001      
       WO       WO 02/04522       A2                1/2002      
       WO       WO 02/07783       A2                1/2002      
       WO       WO 02/27017       A2                4/2002      
       WO       WO 02/31500       A2                4/2002      
       WO       WO 02/43758       A2                6/2002      
       WO       WO 02/053596       A2                7/2002      
       WO       WO 02/054066       A2                7/2002      
       WO       WO 02/072780       A2                9/2002      
       WO       WO 20/04/087756       A2                10/2002      
       WO       WO 02/088752       A2                11/2002      
       WO       WO 02/092599       A1                11/2002      
       WO       WO 02/102854       A2                12/2002      
       WO       WO 02/102972       A2                12/2002      
       WO       WO 02/102973       A2                12/2002      
       WO       WO 03/000928       A2                1/2003      
       WO       WO 03/14696       A2                2/2003      
       WO       WO 03/027246       A2                4/2003      
       WO       WO 03/039538       A1                5/2003      
       WO       WO 03/059951       A2                7/2003      
       WO       WO 03/088910       A2                10/2003      
       WO       WO 03/100008       A2                12/2003      
       WO       WO 03/100059       A2                12/2003      
       WO       WO 03/106621       A2                12/2003      
       WO       WO 03/106621       A2                12/2003      
       WO       WO 20/04/030625       A2                4/2004      
       WO       WO 20/04/030627       A2                4/2004      
       WO       WO 20/04/056865       A2                7/2004      
       WO       WO 20/04/071529       A2                8/2004      
       WO       WO 20/04/083248       A1                9/2004      
       WO       WO20/04/096224       A2                11/2004      
       WO       WO20/04/096224       A3                11/2004      
       WO       WO 20/05/005635       A2                1/2005      
       WO       WO 20/05/016967       A2                2/2005      
       WO       WO 20/05/016970       A2                2/2005      
       WO       WO20/05/052005                         6/2005      
       WO       WO 20/05/061541       A1                7/2005      
       WO       WO20/05/117980       A1                12/2005      
       WO       WO20/06/013472       A2                2/2006      
       WO       WO20/06069202                         6/2006      
       WO       WO20/06/020258       A2                12/2006      
       WO       WO20/07/093008                         8/2007      

 OTHER PUBLICATIONS
  
  Tonini et al. (Curr. Pharm. Design 12:2303-2317 (2006)). *
  Leventhal et al. (Exp. Cell. Res. 221:179-186 (1995)). *
  Singleton et al. (Can. Res. 56:4522-4529 (1996)). *
  Maloney et al. (Can. Res. 63:5073-5083 (2003)). *
  Jain, Scientific American Jul. 1994 pp. 58-65. *
  Chatterjee et al., Cancer Immunol. Imunother., 38:75-82, 1994. *
  Dermer, Biotechnology 12: 320, 1994. *
  Gura et al., Science vol. 278:1041-1042 (Nov. 1997). *
  Seaver, 1994; Genetic Engineering vol. 14(14):10 and 21. *
  Rudikoff et al., Proc Natl Acad Sci USA 1982 vol. 79 p. 1979. *
  Casset et al. (2003) BBRC 307, 198-205. *
  Vajdos et al. (2002) J. Mol. Biol. 320, 415-428. *
  Holm et al., Mol. Immunol. 44, 1075-1084, 2007. *
  Sequence search alignment for SEQ ID Nos. 2, 4, 6, 8, 10 and 12 against US 20040018191 (Wang et al.), pp. 1-6. *
  Sequence search alignment for SEQ ID Nos. 2, 4, 6, 8, 10 and 12 against US 20070059241 (Wang et al.), pp. 1-6. *
  Sequence search alignment for SEQ ID Nos. 2, 4, 6, 8, 10 and 12 against US 20070059305 (Wang et al.), pp. 1-6. *
  Sequence search alignment for SEQ ID Nos. 8 and 10 against US 20050136063 (Wang et al.), pp. 1-2. *
  Sequence search alignment output for SEQ ID No. 13 (see Cohen et al. US 20040202651) pp. 1-3. *
  Sequence search alignment output for SEQ ID No. 14 (see Cohen et al. US 20040202651) pp. 1-5. *
  Sequence search alignment output for SEQ ID No. 15 (see Cohen et al. US 20040202651) pp. 1-3. *
  Sequence search alignment output for SEQ ID No. 19 (see Cohen et al. US 20040202651) pp. 1-5. *
  Dennis (Nature 442:739-741 (2006)). *
  Cespdes et al. (Clin. Transl. Oncol. 8(5):318-329 (2006)). *
  Talmadge et al. (Am. J. Pathol 170(3):793-804 (2007)). *
  Accession No. AAB27175 GenBank (pp. 1-3 (Nov. 17, 2009)). *
  Stefania Benini et al., Inhibition of Insulin-like Growth Factor I Receptor Increases the Antitumor Activity of Doxorubicin and Vincristine Against Ewing's Sarcoma Cells, Clinical Cancer Research, vol. 7, 1790-1797, Jun. 2001.
  V.M. Macaulay, Insulin-like Growth Factors and Cancer, Br. J. Cancer, 65, 311-320, 1992.
  Mariana Resnicoff et al., The Role of the Insulin-like Growth Factor I Receptor in Transformation and Apoptosis, Kimmel Cancer Institute, Thomas Jefferson University pp. 76-81.
  Xiangdang Liu et al., Inhibition of Insulin-like Growth Factor I Receptor Expression in Neuroblastoma Cells Induces the Regression of Established Tumors in Mice, Cancer Research 58, 5432-5438, Dec. 1, 1998.
  Jamie L. Resnik et al., Elevated Insulin-like Growth Factor I Receptor Autophosphorylation and Kinase Activity in Human Breast Cancer, Cancer Research 58, 1159-1164, Mar. 15, 1998.
  Fredrika Pekonen et al., Receptors for Epidermal Growth Factor and Insulin-like Growth Factor I and Their Relation to Steroid Receptors in Human Breast Cancer, Cancer Research 48, 1343-1347, Mar. 1, 1988.
  Quynh T. Rohlik et al., An Antibody to the Receptor for Insulin-like Growth Factor I Inhibits the Growth of MCF-7 Cells in Tissue Culture, Biochemical and Biophysical Research Communications, vol. 149, No. 1, 276-281, 1987.
  Carlos L. Arteaga et al., Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice, J. Clin. Invest., vol. 84, 1418-1423, Nov. 1989.
  Ted Gansler et al., Rapid Communication Antibody to Type I insulinlike Growth Factor Receptor Inhibits Growth of Wilms' Tumor in Culture and in Athymic Mice, American Journal of Pathology, vol. 135, No. 6, 961-966, Dec. 1989.
  Krzysztof Reiss et al., Inhibition of Tumor Growth by a Dominant Negative Mutant of the Insulin-like Growth Factor I Receptor with a Bystander Effect, Clinical Cancer Research, vol. 4, 2647-2655, Nov. 1998.
  Carlos L. Arteaga et al., Growth Inhibition of Human Breast Cancer Cells in Vitro with an Antibody Against the Type I Somatomedin Receptor, Cancer Research, 49, 6237-6241, Nov. 15, 1989.
  Sandra E. Dunn et al., A Dominant Negative Mutant of the Insulin-like Growth Factor-I Receptor Inhibits the Adhesion, Invasion, and Metastasis of Breast Cancer, Cancer Research, 58, 3353-3361, Aug. 1, 1998.
  Peter Burfeind, Antisense RNA to the Type I Insulin-like Growth Factor Receptor Suppresses Tumor Growth and Prevents Invasion by Rate Prostate Cancer Cells In Vivo, Proc. Natl. Acad. Sci. USA, vol. 93 7263-7268, Jul. 1996.
  Diane Prager et al., Dominant Negative Inhibition of Tumorigenesis In Vivo by Human Insulin-like Growth Factor I Receptor Mutant, Proc. Natl. Acad. Sci. USA, vol. 91, 2181-2185, Mar. 1994.
  Deepali Sachdev, A Chimeric Humanized Single-Chain Antibody Against the Type I Insulin-like Growth Factor (IGF) Receptor Renders Breast Cancer Cells Refractory to the Mitogenic Effects of IGF-1, Cancer Research 63, 627-635, 2003.
  Hakam et al., Human Pathology (1999) 30(10): 1128-1133.
  Sepp-Lorenzino, Breast Cancer Research and Treatment (1998) 47: 235-253.
  R&D Systems catalogue pages—monoclonal Anti-human IGF-IR Antibody MAB391.
  Xiong et al., “Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor” Proc. Nat. Acad. Sci. 89: 5356-5360 (1992).
  Li et al., “Two new monoclonal antibodies against the α subunit of the human insulin-like growth factor-I receptor” Biochem. Biophys. Res. Comm. 196(1):92-98 (1993).
  Kull et al., “Monoclonal antibodies to receptors for insulin and somatomedin-C” J. Biol. Chem. 258(10):6561-6566 (1983).
  Butler et al., “Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology” Comp. Biochem. Physiol. Part (B) 121(1):19-26 (1998).
  Chan et al., “Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study” Science. 279(5350):563-566 (1998).
  Xie et al., “Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype” Cancer Res. 59(15):3588-3591 (1999).
  Steller et al., “Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells” Cancer Res. 56(8):1761-1765 (1996).
  Pandini et al., “Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to Insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling” Clin. Cancer Res. 5(7):1935-1944 (1999).
  Webster et al., “Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer” Cancer Res. 56(12):2781-2788 (1996).
  Ben-Schlomo et al., “Acromegaly” Endocrin. Metab. Clin. N. America 30(3):565-583 (2001).
  Li et al., “Single-chain antibodies against human Insulin-like growth factor I receptor: expression, purification, and effect on tumor growth”, Cancer Immunol. Immunother. 49: 243-252 (2000).
  Burtrum et al., “A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and Inhibits human tumor growth in vivo.” Cancer Res. Dec. 15, 2003;63(24):8912-21.
  Business Wire, “Imclone systems incorporated reports advancements in several pipeline programs” (Jul. 14, 2003).
  Zhu, “Monoclonal Antibodies in Cancer-Fourth International Congress (Part II), Colorado Springs, CO, USA” Investigational Drug Database Meeting Report (Sep. 3-6, 2004).
  Williams, “American Association for Cancer Research-94th Annual Meeting (Part III)—Overnight Report, Washington, D.C., USA” Investigational Drug Database Meeting Report (Jul. 11-14, 2003).
  Imclone Systems, Inc. Form 10-K (filed Mar. 15, 2004).
  Holt et al., Domain antibodies: proteins for therapy, Trends in Biotechnology 21(11): 484-490 (2003).
  Maloney et al., An Anti-Insulin-like Growth Factor I Receptor Antibody That Is a Potent Inhibitor of Cancer Cell Proliferation, Cancer Research 63, 5073-5083 (2003).
  Lu et al., Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth factor receptor signaling pathways in cancer cells with a XXX human recombinant XXX antibody, J. Bio. Chem.279(4): 2856-65 (2004).
  Tang et al., Use of a peptide mimotope to guide the humanization of MRK-16, an anti-P-glycoprotein monoclonal antibody. J Biol Chem. Sep. 24, 1999;274(39):27371-8.
  Boylan et al., The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen. Ann Oncol. Feb. 1998;9(2):205-11.
  Happerfield et al., The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol. Dec. 1997;183(4):412-7.
  Clarke et al., Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. Br J Cancer. 1997;75(2):251-7.
  Van Den Berg et al., Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on Insulin-like growth factor I receptor expression. Br J Cancer. Feb. 1996;73(4):477-81.
  Lebon et al., Purification of insulin-like growth factor I receptor from human placental membranes. J Biol Chem. Jun. 15, 1986;261(17):7685-9.
  Warren et al., Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem. Nov. 15, 1996;271(46):29483-8.
  Auclair et al., Antiinsulin receptor autoantibodies induce insulin receptors to constitutively associate with insulin receptor substrate-1 and -2 and cause severe cell resistance to both insulin and insulin-like growth factor I. J Clin Endocrinol Metab. Sep. 1999;84(9):3197-3206.
  Gori et al., Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. Endocrinology. Dec. 1999;140(12):5579-86.
  Kasprzyk et al., Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res. May 15, 1992;52(10):2771-6.
  Drebin et al., Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene. Mar. 1988;2(3):273-7.
  Shin et al., Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies. Cancer Res. Apr. 1, 2005;65(7):2815-24.
  Lu et al., A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem. May 20, 2005;280(20):19665-72.
  Cohen et al., Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res. Mar. 1, 2005;11(5):2063-73.
  Wu et al., In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res. Apr. 15, 2005;11(8):3065-74.
  Goetsch et al., A recombinant humanized anti-insulin-like growth factor receptor type 1 antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer. Jan. 10, 2005;113(2):316-28.
  Granerus et al., Effects of insulin-like growth factor-binding protein 2 and an IGF-type I receptor-blocking antibody on apoptosis in human teratocarcinoma cells in vitro. Cell Biol Int. 2001;25(8):825-8.
  Kaliman et al., Antipeptide antibody to the insulin-like growth factor-I receptor sequence 1232-1246 inhibits the receptor kinase activity. J Biol Chem. May 25, 1992;267(15):10645-51.
  Rodeck et al., Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors. J Cell Biochem. Dec. 1987;35(4):315-20.
  Iwakiri et al., Autocrine growth of Epstein-Barr virus-positive gastric carcinoma cells mediated by an Epstein-Barr virus-encoded small RNA. Cancer Res. Nov. 1, 2003;63(21):7062-7.
  Kiess et al., Human neuroblastoma cells use either insulin-like growth factor-I or insulin-like growth factor-II in an autocrine pathway via the IGF-I receptor: variability of IGF, IGF binding protein (IGFBP) and IGF receptor gene expression and IGF and IGFBP secretion in human neuroblastoma cells in relation to cellular proliferation. Regul Pept. Sep. 26, 1997;72(1):19-29.
  Pritchard et al., Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor. J Immunol. Sep. 1, 2004;173(5):3564-9.
  Jackson-Booth et al., Inhibition of the biologic response to insulin-like growth factor I in MCF-7 breast cancer cells by a new monoclonal antibody to the insulin-like growth factor-I receptor. The importance of receptor down-regulation. Horm Metab Res. Nov.-Dec. 2003;35(11-12):850-6.
  Carboni et al., Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res. May 1, 2005;65(9):3781-7.
  Remacle-Bonnet et al., Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res. Apr. 1, 2000;60(7):2007-17.
  Lahm et al., Blockade of the insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II-mediated autocrine loop. Int J Cancer. Aug. 1, 1994;58(3):452-9.
  Steele-Perkins et al., Monoclonal antibody alpha IR-3 inhibits the ability of insulin-like growth factor II to stimulate a signal from the type I receptor without inhibiting its binding. Biochem Biophys Res Commun. Sep. 28, 1990;171(3):1244-51.
  Scotlandi et al., Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer. Jun. 2005;41(9):1349-61.
  Agus et al., Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. Oct. 1, 1999;59(19):4761-4.
  Pietras et al., Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. Mar. 15, 1999;59(6):1347-55.
  Goldenberg, Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. Feb. 1999;21(2):309-18. Review.
  Seely et al., Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo. BMC Cancer. May 31, 2002;2:15.
  Soos et al., A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. J Biol Chem. Jun. 25, 1992;267(18):12955-63.
  Kalebic et al., In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res. Nov. 1, 1994;54(21):5531-4.
  Baserga, The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res. Jan. 15, 1995;55(2):249-52.
  Rubini et al., Characterization of an antibody that can detect an activated IGF-I receptor in human cancers. Exp Cell Res. Aug. 25, 1999;251(1):22-32.
  Lin et al., Structure-function relationships in glucagon: properties of highly purified des-His-1-, monoiodo-, and (des-Asn- 28, Thr-29)(homoserine lactone -27)-glucagon, Biochemistry. Apr. 22, 1975;14(8):1559-63.
  Acland et al., Subcellular fate of the int-2 oncoprotein is determined by choice of initiation codon, Nature. Feb. 15, 1990;343(6259):662-5.
  Cordera et al., Inhibition of insulin and epidermal growth factor (EGF) receptor autophosphorylation by a human polyclonal 1gG, Biochem Biophys Res Commun. Nov. 15, 1985;132(3):991-1000.
  Freund et al., Functional insulin and insulin-like growth factor-1 receptors are preferentially expressed in multiple myeloma cell lines as compared to B-lymphoblastoid cell lines, Cancer Res. Jun. 15, 1994;54(12):3179-85.
  Rudikoff et al., Single amino acid substitution altering antigen-binding specificity, Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
  Burgess et al., Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue, J Cell Biol. Nov. 1990;111:2129-38.
  Lazar et al., Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities, Mol Cell Biol. Mar. 1988;8(3):1247-52.
  Schwartz et al., A superactive insulin: [B10-aspartic acid]insulin(human), Proc Natl Acad Sci U S A. Sep. 1987;84(18):6408-11.
  Jackson et al., Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem. Apr. 17, 1998;273(16):9994-10003.
  Desnoyers et al., Novel non-isotopic method for the localization of receptors in tissue sections. J Histochem Cytochem. Dec. 2001;49(12):1509-18.
  Ricort et al. Insulin-like growth factor (IGF) binding protein-3 inhibits type 1 IGF receptor activation independently of its IGF binding affinity, Endocrinology. Jan. 2001;142(1):108-13.
  International Search Report for application No. PCT/US2005/043184.
  Hailey et al., Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol. Cancer Therap. 1:1349-1353 (2002).
  Bagatell et al., Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int J Cancer. Jan. 10, 2005;113(2):179-88.
  Baserga, Targeting the IGF-1 receptor: from rags to riches. Eur. J. Cancer. Sep. 2004;40(14):2013-5.
  García-Echeverría et al., In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. Mar. 2004;5(3):231-9.
  Resnicoff et al., Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors.Cancer Res. Apr. 15, 1994;54(8):2218-22.
  Wittman et al., Discovery of a (1H-benzoimidazol-2-y1)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.J Med Chem. Sep. 8, 2005;48(18):5639-43.
  Clemmons, Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer.Nat Rev Drug Discov. Oct. 2007;6(10):821-33.
  Noble et al., Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. Sep. 1997;54(3):447-72.
  Maloney et al., An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. Aug. 15, 2003;63(16):5073-83.
  Pandini et al., Functional responses and in vivo anti-tumour activity of h7c10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer. May 2007;43(8):1318-27.
  Burtrum et al., A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.Cancer Res. Dec. 15, 2003;63(24):8912-21.
  Cohen et al., Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.Clin Cancer Res. Mar. 1, 2005;11(5):2063-73.
  Ji et al., A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.Mol Cancer Ther. Aug. 2007;6(8):2158-67.
  Yang et al., Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.Cancer Res. Feb. 15, 2007;67(4):1716-24.
  Yeo et al., YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.J Natl Cancer Inst. Apr. 2, 2003;95(7):516-25.
  Albert et al., Responsiveness of human retinoblastoma and neuroblastoma models to a non-calcemic 19-nor Vitamin D analog. J Steroid Biochem Mol Biol. Oct. 2005;97(1-2):165-72.
  Wagner et al., Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. Clin Cancer Res. Sep. 15, 2007;13(18 Pt 1):5418-25.
  Armstrong et al., Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo. Br J Cancer. Jun. 4, 2007;96(11):1675-83.
  Beech et al., Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol, Oncology Reports (2001) 8:325-329.
  Pollak et al., Insulin-like growth factors and neoplasiaNat Rev Cancer. Jul. 2004;4(7):505-18.
  Herceptin®: US BLA supplement.
  Clinicaltrials.gov entry: A phase 2 study of AMG479 in relapsed or refractory Ewing's family tumor and desmoplastic small round cell tumors.
  Clinicaltrials.gov entry: Phase 2 study of CP-751871 in combination with docetaxel and prednisone in patients with hormone insensitive prostate cancer (HRPC).
  Clinicaltrials.gov entry: Study using IMC-A12 with or without cetuximab in patients with metastatic colorectal cancer who have failed a treatment regimen that consisted of a prior anti-EGFr therapy.
  Clinicaltrials.gov entry: A study of R1507 in patients with recurrent or refractory sarcoma.
  Clinicaltrials.gov entry: A study to determine the activity of SCH717454 in subjects with relapsed osteosarcoma or Ewing's sarcoma (Study P04720).
  Clinicaltrials.gov entry: Preoperative Octreotide Treatment of Acromegaly (POTA).
  Clinicaltrials.gov entry: Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies.
  Niu T, Rosen CJ. The insulin-like growth factor-I gene and osteoporosis: a critical appraisal. Gene. Nov. 21, 2005;361:38-56.
  Steele-Perkins G, Turner J, Edman JC, Hari J, Pierce SB, Stover C, Rutter WJ, Roth RA. Expression and characterization of a functional human insulin-like growth factor I receptor. J Biol Chem. Aug. 15, 1988;263(23):11486-11492.
  Chang Q, Li Y, White MF, Fletcher JA, Xiao S. Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications. Cancer Res. Nov. 1, 2002;62(21):6035-6038.
  Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer. Jun. 2008;50(6):1190-1197.
  Lopaczynski W, Terry C. Insulin-like growth factor I activates insulin receptor substrate 1 and Ras in human osteosarcoma cells. Acta Biochim Pol. 1999;46(1):117-123.
  Wang et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther. Aug. 2005;4(8):1214-21.
  International Non-proprietary Names for Pharmaceutical Substances (INN), Cumulative list No. 12, 2007.
  Statement on a Nonproprietary Name Adopted by the USAN Council (2008).
 
 
     * cited by examiner
 
     Primary Examiner —Lynn Bristol
     Art Unit — 1643
     Exemplary claim number — 1

(57)

Abstract

The present invention provides methods for identifying patients whose cancers are likely to be responsive to IGF1R inhibitory anti-cancer therapy along with methods for treating such patients. Patients identified by a method of the present invention can be treated with any of several known IGF1R inhibitory agents including antibodies, small molecule inhibitors and anti-sense nucleic acids.
16 Claims, 5 Drawing Sheets, and 5 Figures


[0001] The present application claims the benefit of U.S. provisional patent application No. 60/633,156; filed Dec. 3, 2004, which is herein incorporated by reference in its entirety.

FIELD OF THE INVENTION

[0002] The present invention relates to methods for selecting patients for anti-cancer therapy.

BACKGROUND OF THE INVENTION

[0003] The insulin-like growth factors, also known as somatomedins, include insulin-like growth factor-I (IGF-I) and insulin-like growth factor-II (IGF-II) (Klapper, et al., (1983) Endocrinol. 112:2215 and Rinderknecht, et al., (1978) Febs. Lett. 89:283). These growth factors exert mitogenic activity on various cell types, including tumor cells (Macaulay, (1992) Br. J. Cancer 65:311), by binding to a common receptor named the insulin-like growth factor receptor-1 (IGF1R) (Sepp-Lorenzino, (1998) Breast Cancer Research and Treatment 47:235). Interaction of IGFs with IGF1R activates the receptor by triggering autophosphorylation of the receptor on tyrosine residues (Butler, et al., (1998) Comparative Biochemistry and Physiology 121:19). Once activated, IGF1R, in turn, phosphorylates intracellular targets to activate cellular signaling pathways. This receptor activation is critical for stimulation of tumor cell growth and survival. Therefore, inhibition of IGF1R activity represents a valuable potential method to treat or prevent growth of human cancers and other proliferative diseases.
[0004] Several lines of evidence indicate that IGF-I, IGF-II and their receptor IGF1R are important mediators of the malignant phenotype. Plasma levels of IGF-I have been found to be the strongest predictor of prostate cancer risk (Chan, et al., (1998) Science 279:563) and similar epidemiological studies strongly link plasma IGF-I levels with breast, colon and lung cancer risk.
[0005] Overexpression of Insulin-like Growth Factor Receptor-1 has also been demonstrated in several cancer cell lines and tumor tissues. IGF1R is overexpressed in 40% of all breast cancer cell lines (Pandini, et al., (1999) Cancer Res. 5:1935) and in 15% of lung cancer cell lines. In breast cancer tumor tissue, IGF1R is overexpressed 6-14 fold and IGF1R exhibits 2-4 fold higher kinase activity as compared to normal tissue (Webster, et al., (1996) Cancer Res. 56:2781 and Pekonen, et al., (1998) Cancer Res. 48:1343). Ninety percent of colorectal cancer tissue biopsies exhibit elevated IGF1R levels wherein the extent of IGF1R expression is correlated with the severity of the disease. Analysis of primary cervical cancer cell cultures and cervical cancer cell lines revealed 3- and 5-fold overexpression of IGF1R, respectively, as compared to normal ectocervical cells (Steller, et al., (1996) Cancer Res. 56:1762). Expression of IGF1R in synovial sarcoma cells also correlated with an aggressive phenotype (i.e., metastasis and high rate of proliferation; Xie, et al., (1999) Cancer Res. 59:3588).
[0006] Currently, there are several known anti-cancer therapies that target IGF1R. For example, anti-IGF1R antibodies are owned by Schering Corp (see WO 2003/100008); Pfizer (see WO 2002/53596 or WO 2004/71529); Pierre Fabre medicament (see WO 2003/59951), Pharmacia Corp. (see WO 2004/83248), Immunogen, Inc. (see WO 2003/106621), Hoffman La Roche (see WO 2004/87756) and Imclone Systems Inc. (IMC-A12; see Burtrum et. al Cancer Research 63:8912-8921(2003)). Additionally, Novartis owns a small molecule IGFR inhibitor, NVP-ADW-742 (see WO 2002/92599) as does Biotech Research Ventures PTE Ltd (see WO 2003/39538). Antisense Therapeutics Ltd. also owns an anti-sense therapy that inhibits IGF1R expression, ATL-1101.
[0007] Agents that decrease IGF1R function and/or expression are effective in the treatment of some cancer patients. However, it is expected that a portion of cancer patients may not respond to such treatments. Therefore, a need exists in the art for a method to identify specific cancer populations and/or specific cancer patients who are most likely to respond to one or more anti-cancer therapies that target IGF1R.

SUMMARY OF THE INVENTION

[0008] The present invention provides, inter alia, a method for treating cancers by pre-selecting patients whose tumors express appreciable levels of IGF-II and/or phosphorylated IRS-1 (insulin receptor substrate-1), thereby increasing the likelihood of a response, in the patient, to therapeutics targeting IGF1R.
[0009] The present invention provides a method for treating a tumor in a patient comprising (a) selecting a patient or patient population having a tumor known to express one or more of the following:
[0010] (i) IRS-1 phosphorylation on tyrosine 896;
[0011] (ii) IRS-1 phosphorylation on tyrosine 612;
[0012] (iii) IRS-1 phosphorylation on any tyrosine;
[0013] (iv) IGF-II;
[0014] (v) IGF1R phosphorylation on any tyrosine; or
[0015] (vi) IGF1R; and

(b) administering to said patient a therapeutically effective amount of an IGF1R inhibitory agent.

[0016] The present invention comprises a method for treating a tumor in a patient comprising: (a) selecting a patient having a tumor expressing one or more of the following:
[0017] (i) IRS-1 phosphorylation on tyrosine 896;
[0018] (ii) IRS-1 phosphorylation on tyrosine 612;
[0019] (iii) IRS-1 phosphorylation on any tyrosine;
[0020] (iv) IGF-II;
[0021] (v) IGF1R phosphorylation on any tyrosine; or
[0022] (vi) IGF1R; and
[0023] (b) administering to said patient a therapeutically effective amount of an IGF1R inhibitory agent. In an embodiment of the invention, the cancer is selected from the group consisting of bladder cancer, Wilm's cancer, bone cancer, prostate cancer, lung cancer, non-small cell lung cancer (NSCLC), colon cancer, rectal cancer, colorectal cancer, endometrial cancer, multiple myeloma, estrogen receptor-positive breast cancer, estrogen receptor-negative breast cancer, cervical cancer, synovial sarcoma, ovarian cancer, pancreatic cancer, neuroblastoma, rhabdomyosarcoma, osteosarcoma and vasoactive intestinal peptide secreting tumors. In an embodiment of the invention, the agent is selected from the group consisting of an isolated antibody or antigen-binding fragment thereof that binds specifically to human IGF1R and is a member selected from the group consisting of: (i) an isolated antibody or antigen-binding fragment thereof that binds specifically to human IGF1R comprising one or more CDRs from a light chain variable region comprising amino acids 20-128 of SEQ ID NO: 8 and/or one or more CDRs from a heavy chain variable region comprising amino acids 20-137 of SEQ ID NO: 10; (ii) an isolated antibody or antigen-binding fragment thereof comprising one or more CDRs from a heavy chain immunoglobulin comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 19-28, 35-38, 43, 45 or 73-98;
(iii) an isolated antibody or antigen-binding fragment thereof comprising one or more CDRs from a light chain immunoglobulin comprising the amino acid sequence of SEQ ID NO: 10, 12-18, 29-34, 39, 40, 41, 42, 44 or 58-72; and (iv) an isolated single-chain antibody (scfv) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 46-51; or
(v)
[0024]  [see pdf for image]
or ATL-1101. In an embodiment of the invention, the isolated antibody or antigen-binding fragment thereof comprises: (i) an isolated immunoglobulin heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 19-28, 35-38, 43, 45 and 73-98; (ii) an isolated immunoglobulin light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 12-18, 29-34, 39, 40, 41, 42, 44 and 58-72; (iii) an isolated antibody produced by a hybridoma deposited at the American Type Culture Collection under deposit number PTA-2792, PTA-2788, PTA-2790, PTA-2791, PTA-2789 or PTA-2793; (iv) an isolated antibody or antigen-binding fragment thereof that binds specifically to human IGF1R comprising a light chain variable region comprising amino acids 20-128 of SEQ ID NO: 8 and/or a heavy chain variable region comprising amino acids 20-137 of SEQ ID NO: 10; and/or (v) an isolated antibody comprising an immunoglobulin light chain encoded by the plasmid contained in the cell line deposited at the American Type Culture Collection under deposit number PTA-5220 and an immunoglobulin heavy chain encoded by the plasmid contained in a cell line deposited at the American Type Culture Collection under deposit number PTA-5214 or PTA-5216. In an embodiment of the invention, phosphorylation of tyrosine on IRS-1 or IGF1R is determined by western blot analysis, ELISA or flow cytometry analysis. In an embodiment of the invention, IGF-II expression is determined by western blot analysis, ELISA, quantitative PCR or by northern blot analysis. In an embodiment of the invention, IGF1R expression is determined by western blot analysis or ELISA.
[0025] The present invention provides a method for selecting a therapy for a patient or a patient population with a tumor, comprising: (a) determining whether the patient's tumor is known to express one or more of the following:
[0026] (i) IRS-1 phosphorylation on tyrosine 896;
[0027] (ii) IRS-1 phosphorylation on tyrosine 612;
[0028] (iii) IRS-1 phosphorylation on any tyrosine;
[0029] (iv) IGF-II;
[0030] (v) IGF1R phosphorylation on any tyrosine; or
[0031] (vi) IGF1R; and/or

(b) determining whether the patient's tumor expresses one or more of the following:

[0032] (i) IRS-1 phosphorylation on tyrosine 896;
[0033] (ii) IRS-1 phosphorylation on tyrosine 612;
[0034] (iii) IRS-1 phosphorylation on any tyrosine;
[0035] (iv) IGF-II;
[0036] (v) IGF1R phosphorylation on any tyrosine; or
[0037] (vi) IGF1R; and
[0038] (c) selecting an IGF1R inhibitory agent as the therapy if the patient's tumor is known to express one or more of (i)-(vi) and/or if the patient's tumor expresses one or more of (i)-(vi). In an embodiment of the invention, the agent is selected from the group consisting of an isolated antibody or antigen-binding fragment thereof that binds specifically to human IGF1R and is a member selected from the group consisting of: (i) an isolated antibody or antigen-binding fragment thereof that binds specifically to human IGF1R comprising one or more CDRs from a light chain variable region comprising amino acids 20-128 of SEQ ID NO: 8 and/or a one or more CDRs from a heavy chain variable region comprising amino acids 20-137 of SEQ ID NO: 10; (ii) an isolated antibody or antigen-binding fragment thereof comprising one or more CDRs from a heavy chain immunoglobulin comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 19-28, 35-38, 43, 45 or 73-98; (iii) an isolated antibody or antigen-binding fragment thereof comprising one or more CDRs from a light chain immunoglobulin comprising the amino acid sequence of SEQ ID NO: 10, 12-18, 29-34, 39, 40, 41, 42, 44 or 58-72; and (iv) an isolated single-chain antibody (scfv) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 46-51; or
[0039]  [see pdf for image]
or ATL-1101. In an embodiment of the invention, the isolated antibody or antigen-binding fragment thereof comprises: (i) an isolated immunoglobulin heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 19-28, 35-38, 43, 45 and 73-98; (ii) an isolated immunoglobulin light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 12-18, 29-34, 39, 40, 41, 42, 44 and 58-72; (iii) an isolated antibody produced by a hybridoma deposited at the American Type Culture Collection under deposit number PTA-2792, PTA-2788, PTA-2790, PTA-2791, PTA-2789 or PTA-2793; (iv) an isolated antibody or antigen-binding fragment thereof that binds specifically to human IGF1R comprising a light chain variable region comprising amino acids 20-128 of SEQ ID NO: 8 and/or a heavy chain variable region comprising amino acids 20-137 of SEQ ID NO: 10; and/or (v) an isolated antibody comprising an immunoglobulin light chain encoded by the plasmid contained in the cell line deposited at the American Type Culture Collection under deposit number PTA-5220 and an immunoglobulin heavy chain encoded by the plasmid contained in a cell line deposited at the American Type Culture Collection under deposit number PTA-5214 or PTA-5216.
[0040] The present invention also provides a method for advertising an IGF1R inhibitory agent or a pharmaceutically acceptable composition thereof comprising promoting, to a target audience, the use of the agent or pharmaceutical composition thereof for treating a patient or patient population whose tumors express or are known to express one or more of the following:
[0041] (i) IRS-1 phosphorylation on tyrosine 896;
[0042] (ii) IRS-1 phosphorylation on tyrosine 612;
[0043] (iii) IRS-1 phosphorylation on any tyrosine;
[0044] (iv) IGF-II;
[0045] (v) IGF1R phosphorylation on any tyrosine; or
[0046] (vi) IGF1R.
[0047] In an embodiment of the invention, the agent is selected from the group consisting of an isolated antibody or antigen-binding fragment thereof that binds specifically to human IGF1R and is a member selected from the group consisting of: (i) an isolated antibody or antigen-binding fragment thereof that binds specifically to human IGF1R comprising one or more CDRs from a light chain variable region comprising amino acids 20-128 of SEQ ID NO: 8 and/or one or more CDRs from a heavy chain variable region comprising amino acids 20-137 of SEQ ID NO: 10; (ii) an isolated antibody or antigen-binding fragment thereof comprising one or more CDRs from a heavy chain immunoglobulin comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 19-28, 35-38, 43, 45 or 73-98; (iii) an isolated antibody or antigen-binding fragment thereof comprising one or more CDRs from a light chain immunoglobulin comprising the amino acid sequence of SEQ ID NO: 10, 12-18, 29-34, 39, 40, 41, 42, 44 or 58-72; and (iv) an isolated single-chain antibody (scfv) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 46-51; or
[0048]  [see pdf for image]
or ATL-1101. In an embodiment of the invention, the isolated antibody or antigen-binding fragment thereof comprises: (i) an isolated immunoglobulin heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 19-28, 35-38, 43, 45 and 73-98; (ii) an isolated immunoglobulin light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 12-18, 29-34, 39, 40, 41, 42, 44 and 58-72; (iii) an isolated antibody produced by a hybridoma deposited at the American Type Culture Collection under deposit number PTA-2792, PTA-2788, PTA-2790, PTA-2791, PTA-2789 or PTA-2793; (iv) an isolated antibody or antigen-binding fragment thereof that binds specifically to human IGF1R comprising a light chain variable region comprising amino acids 20-128 of SEQ ID NO: 8 and/or a heavy chain variable region comprising amino acids 20-137 of SEQ ID NO: 10; and/or (v) an isolated antibody comprising an immunoglobulin light chain encoded by the plasmid contained in the cell line deposited at the American Type Culture Collection under deposit number PTA-5220 and an immunoglobulin heavy chain encoded by the plasmid contained in a cell line deposited at the American Type Culture Collection under deposit number PTA-5214 or PTA-5216.
[0049] The present invention also provides an article of manufacture comprising, packaged together, a pharmaceutical composition comprising an IGF1R inhibitory agent and a pharmaceutically acceptable carrier and a label stating that the agent or pharmaceutical composition is indicated for treating patients having a tumor expressing or known to express one or more of the following:
[0050] (i) IRS-1 phosphorylation on tyrosine 896;
[0051] (ii) IRS-1 phosphorylation on tyrosine 612;
[0052] (iii) IRS-1 phosphorylation on any tyrosine;
[0053] (iv) IGF-II;
[0054] (v) IGF1R phosphorylation on any tyrosine; or
[0055] (vi) IGF1R.
[0056] In an embodiment of the invention, the agent is selected from the group consisting of an isolated antibody or antigen-binding fragment thereof that binds specifically to human IGF1R and is a member selected from the group consisting of: (i) an isolated antibody or antigen-binding fragment thereof that binds specifically to human IGF1R comprising one or more CDRs from a light chain variable region comprising amino acids 20-128 of SEQ ID NO: 8 and/or a one or more CDRs from a heavy chain variable region comprising amino acids 20-137 of SEQ ID NO: 10; (ii) an isolated antibody or antigen-binding fragment thereof comprising one or more CDRs from a heavy chain immunoglobulin comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 19-28, 35-38, 43, 45 or 73-98; (iii) an isolated antibody or antigen-binding fragment thereof comprising one or more CDRs from a light chain immunoglobulin comprising the amino acid sequence of SEQ ID NO: 10, 12-18, 29-34, 39, 40, 41, 42, 44 or 58-72; and (iv) an isolated single-chain antibody (scfv) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 46-51; or
[0057]  [see pdf for image]
or ATL-1101. In an embodiment of the invention, the isolated antibody or antigen-binding fragment thereof comprises: (i) an isolated immunoglobulin heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 19-28, 35-38, 43, 45 and 73-98; (ii) an isolated immunoglobulin light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 12-18, 29-34, 39, 40, 41, 42, 44 and 58-72; (iii) an isolated antibody produced by a hybridoma deposited at the American Type Culture Collection under deposit number PTA-2792, PTA-2788, PTA-2790, PTA-2791, PTA-2789 or PTA-2793; (iv) an isolated antibody or antigen-binding fragment thereof that binds specifically to human IGF1R comprising a light chain variable region comprising amino acids 20-128 of SEQ ID NO: 8 and/or a heavy chain variable region comprising amino acids 20-137 of SEQ ID NO: 10; and/or (v) an isolated antibody comprising an immunoglobulin light chain encoded by the plasmid contained in the cell line deposited at the American Type Culture Collection under deposit number PTA-5220 and an immunoglobulin heavy chain encoded by the plasmid contained in a cell line deposited at the American Type Culture Collection under deposit number PTA-5214 or PTA-5216.
[0058] The present invention further provides a method for manufacturing an IGF1R inhibitory agent or a pharmaceutical composition thereof comprising combining in a package the agent or pharmaceutical composition and a label stating that the agent or pharmaceutical composition is indicated for treating patients having a tumor expressing or known to express one or more of the following:
[0059] (i) IRS-1 phosphorylation on tyrosine 896;
[0060] (ii) IRS-1 phosphorylation on tyrosine 612;
[0061] (iii) IRS-1 phosphorylation on any tyrosine;
[0062] (iv) IGF-II;
[0063] (v) IGF1R phosphorylation on any tyrosine; or
[0064] (vi) IGF1R.
[0065] In an embodiment of the invention, the agent is selected from the group consisting of an isolated antibody or antigen-binding fragment thereof that binds specifically to human IGF1R and is a member selected from the group consisting of: (i) an isolated antibody or antigen-binding fragment thereof that binds specifically to human IGF1R comprising one or more CDRs from a light chain variable region comprising amino acids 20-128 of SEQ ID NO: 8 and/or a one or more CDRs from a heavy chain variable region comprising amino acids 20-137 of SEQ ID NO: 10; (ii) an isolated antibody or antigen-binding fragment thereof comprising one or more CDRs from a heavy chain immunoglobulin comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 19-28, 35-38, 43, 45 or 73-98; (iii) an isolated antibody or antigen-binding fragment thereof comprising one or more CDRs from a light chain immunoglobulin comprising the amino acid sequence of SEQ ID NO: 10, 12-18, 29-34, 39, 40, 41, 42, 44 or 58-72; and (iv) an isolated single-chain antibody (scfv) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 46-51;
[0066]  [see pdf for image]
or ATL-1101. In an embodiment of the invention, the isolated antibody or antigen-binding fragment thereof comprises: (i) an isolated immunoglobulin heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 19-28, 35-38, 43, 45 and 73-98; (ii) an isolated immunoglobulin light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 12-18, 29-34, 39, 40, 41, 42, 44 and 58-72; (iii) an isolated antibody produced by a hybridoma deposited at the American Type Culture Collection under deposit number PTA-2792, PTA-2788, PTA-2790, PTA-2791, PTA-2789 or PTA-2793; (iv) an isolated antibody or antigen-binding fragment thereof that binds specifically to human IGF1R comprising a light chain variable region comprising amino acids 20-128 of SEQ ID NO: 8 and/or a heavy chain variable region comprising amino acids 20-137 of SEQ ID NO: 10; and/or (v) an isolated antibody comprising an immunoglobulin light chain encoded by the plasmid contained in the cell line deposited at the American Type Culture Collection under deposit number PTA-5220 and an immunoglobulin heavy chain encoded by the plasmid contained in a cell line deposited at the American Type Culture Collection under deposit number PTA-5214 or PTA-5216.
[0067] The present invention also provides a method for identifying a patient whose tumor is likely to be responsive to an IGF1R inhibitory agent comprising: (a) determining whether the patient has a tumor known to express one or more of the following:
[0068] (i) IRS-1 phosphorylation on tyrosine 896;
[0069] (ii) IRS-1 phosphorylation on tyrosine 612;
[0070] (iii) IRS-1 phosphorylation on any tyrosine;
[0071] (iv) IGF-II;
[0072] (v) IGF1R phosphorylation on any tyrosine; or
[0073] (vi) IGF1R; and/or

(b) determining whether the patient has a tumor expressing one or more of the following:

[0074] (i) IRS-1 phosphorylation on tyrosine 896;
[0075] (ii) IRS-1 phosphorylation on tyrosine 612;
[0076] (iii) IRS-1 phosphorylation on any tyrosine;
[0077] (iv) IGF-II;
[0078] (v) IGF1R phosphorylation on any tyrosine; or
[0079] (vi) IGF1R.
[0080] In an embodiment of the invention, the agent is selected from the group consisting of an isolated antibody or antigen-binding fragment thereof that binds specifically to IGF1R and is a member selected from the group consisting of: (i) an isolated antibody or antigen-binding fragment thereof that binds specifically to human IGF1R comprising one or more CDRs from a light chain variable region comprising amino acids 20-128 of SEQ ID NO: 8 and/or a one or more CDRs from a heavy chain variable region comprising amino acids 20-137 of SEQ ID NO: 10; (ii) an isolated antibody or antigen-binding fragment thereof comprising one or more CDRs from a heavy chain immunoglobulin comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 19-28, 35-38, 43, 45 or 73-98; (iii) an isolated antibody or antigen-binding fragment thereof comprising one or more CDRs from a light chain immunoglobulin comprising the amino acid sequence of SEQ ID NO: 10, 12-18, 29-34, 39, 40, 41, 42, 44 or 58-72; and (iv) an isolated single-chain antibody (scfv) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 46-51; or (v)
[0081]  [see pdf for image]
or ATL-1101. In an embodiment of the invention, the isolated antibody or antigen-binding fragment thereof comprises: (i) an isolated immunoglobulin heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 19-28, 35-38, 43, 45 and 73-98; (ii) an isolated immunoglobulin light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 12-18, 29-34, 39, 40, 41, 42, 44 and 58-72; (iii) an isolated antibody produced by a hybridoma deposited at the American Type Culture Collection under deposit number PTA-2792, PTA-2788, PTA-2790, PTA-2791, PTA-2789 or PTA-2793; (iv) an isolated antibody or antigen-binding fragment thereof that binds specifically to human IGF1R comprising a light chain variable region comprising amino acids 20-128 of SEQ ID NO: 8 and/or a heavy chain variable region comprising amino acids 20-137 of SEQ ID NO: 10; and/or (v) an isolated antibody comprising an immunoglobulin light chain encoded by the plasmid contained in the cell line deposited at the American Type Culture Collection under deposit number PTA-5220 and an immunoglobulin heavy chain encoded by the plasmid contained in a cell line deposited at the American Type Culture Collection under deposit number PTA-5214 or PTA-5216.

BRIEF DESCRIPTION OF THE FIGURES

[0082] FIG. 1. IRS-1 Phosphorylation is Higher in Human Lung Tumor vs. Normal Tissue Samples. Western blot analysis results for normal and tumor tissue samples from four different patients. Lanes marked “T” contained tumor tissue and lanes marked “N” contained normal tissue.
[0083] FIG. 2. Antibody 19D12/15H12 LCF/HCA: In Vivo Efficacy. The level of tumor growth inhibition observed in xenograft mice administered antibody 19D12/15H12 LCF/HCA is indicated along with the type of tumor evaluated and the cell line used to establish each tumor.
[0084] FIG. 3. In Vivo Efficacy of 19D12/15H12 LCF/HCA Correlates with Sensitivity of IRS-1 Phosphorylation to IGF-I. In the “−” and “+” lanes, the quantity of phosphorylated IRS-1, in each cell line evaluated, is shown in the absence and presence of IGF-I, respectively. The level of in vivo efficacy of 19D12/15H12 LCF/HCA at inhibiting growth of the indicated cell line (see FIG. 2) is also indicated.
[0085] FIG. 4. Overexpression of IGF-II mRNA in Human Ovarian Tumor Samples. The normalized level of IGF-II mRNA expression observed in each of the 20 normal ovarian tissue samples and 36 cancerous ovarian tissue samples is shown.
[0086] FIG. 5. Overexpression of IGF-II mRNA in Human Colorectal Tumor Samples. The normalized level of IGF-II mRNA expression observed in each of the 36 normal ovarian tissue samples and 36 cancerous colorectal tissue samples is shown.

DETAILED DESCRIPTION OF THE INVENTION

[0087] The present invention provides a method for treating cancer or for identifying patients whose cancer is likely to be responsive to an IGF1R inhibitory agent. The method is useful, inter alia, for increasing the likelihood that administration of an IGF1R inhibitory anti-cancer therapy to a patient will be efficacious.
[0088] The terms “IGF1R”, “IGFR1”, “Insulin-like Growth Factor Receptor-I” and “Insulin-like Growth Factor Receptor, type I” are well known in the art. Although IGF1R may be from any organism, it is preferably from an animal, more preferably from a mammal (e.g., mouse, rat, rabbit, sheep or dog) and most preferably from a human. The nucleotide and amino acid sequence of a typical human IGF1R precursor has the Genbank Accession No. X04434 or NM000875. Cleavage of the precursor (e.g., between amino acids 710 and 711) produces an α-subunit and a β-subunit which associate to form a mature receptor.
[0089] The terms “IGF-I” “Insulin-like Growth Factor-I” and “Insulin-like Growth Factor, type I” are also well known in the art. The terms “IGF-II” “Insulin-like Growth Factor-II” and “Insulin-like Growth Factor, type II” are also well known in the art. Although IGF-I or IGF-II may be from any organism, they are preferably from an animal, more preferably from a mammal (e.g., mouse, rat, rabbit, sheep or dog) and most preferably from a human. The nucleic acid and amino acid sequence of typical, human IGF-I and IGF-II have the Genbank Accession No. XM052648 and NM000612, respectively.

IGF1R Inhibitory Agents

[0090] The term “IGF1R inhibitory agent” includes any substance that decreases the expression, ligand binding, kinase activity or any other biological activity of IGF1R that will elicit a biological or medical response of a tissue, system, subject or patient that is being sought by the administrator (such as a researcher, doctor or veterinarian) which includes any measurable alleviation of the signs, symptoms and/or clinical indicia of cancer (e.g., tumor growth) and/or the prevention, slowing or halting of progression or metastasis of cancer to any degree.
[0091] In an embodiment of the invention, an IGF1R inhibitory agent that can be administered to a patient in a method according to the invention is any isolated anti-insulin-like growth factor receptor-1 (IGF1R) antibody or fragment thereof (e.g., monoclonal antibodies (e.g., fully human monoclonal antibodies), polyclonal antibodies, bispecific antibodies, Fab antibody fragments, F(ab)2 antibody fragments, Fv antibody fragments (e.g., VH or VL), single chain Fv antibody fragments, dsFv antibody fragments, humanized antibodies, chimeric antibodies or anti-idiotypic antibodies) such as any of those disclosed in any of Burtrum et. al Cancer Research 63:8912-8921(2003); in French Patent Applications FR2834990, FR2834991 and FR2834900 and in PCT Application Publication Nos. WO 03/100008; WO 03/59951; WO 04/71529; WO 03/106621; WO 04/83248; WO 04/87756 and WO 02/53596.
[0092] In an embodiment of the invention, an IGF1R inhibitory agent that can be administered to a patient in a method according to the invention is an isolated anti-insulin-like growth factor receptor-1 (IGF1R) antibody comprising a mature or unprocessed 19D12/15H12 Light Chain-C, D, E or F and a mature 19D12/15H12 heavy chain-A or B. In an embodiment of the invention, an IGF1R inhibitory agent that can be administered to a patient in a method according to the invention is an isolated antibody that specifically binds to IGF1R that comprises one or more complementarity determining regions (CDRs) of 19D12/15H12 Light Chain-F and/or 19D12/15H12 heavy chain-A (e.g., all 3 light chain CDRs and all 3 heavy chain CDRs).
[0093] The amino acid and nucleotide sequences of the 19D12/15H12 antibody chains are shown below. Dotted, underscored type indicates the signal peptide. Solid underscored type indicates the CDRs. Plain type indicates the framework regions. Mature fragments lack the signal peptide.
[0094] 
[00001] [TABLE-US-00001]
 
  Modified 19D12/15H12 Light Chain-C (SEQ ID NO: 1)
 
[see pdf for image]
 
  (SEQ ID NO: 2)
 
[see pdf for image]
 
  Modified 19D12/15H12 Light Chain-D (SEQ ID NO: 3)
 
[see pdf for image]
 
  (SEQ ID NO: 4)
 
[see pdf for image]
 
  Modified 19D12/15H12 Light Chain-E (SEQ ID NO: 5)
 
[see pdf for image]
 
  (SEQ ID NO: 6)
 
[see pdf for image]
 
  19D12/15H12 Light Chain-F (LCF; SEQ ID NO: 7)
 
[see pdf for image]
 
  (SEQ ID NO: 8)
 
[see pdf for image]
 
  19D12/15H12 heavy chain-A (HCA; SEQ ID NO: 9)
 
[see pdf for image]
 
  (SEQ ID NO: 10)
 
[see pdf for image]
 
  Modified 19D12/15H12 heavy chain-B (SEQ ID NO: 11)
 
[see pdf for image]
 
  (SEQ ID NO: 12)
 
[see pdf for image]
 
[0095] Plasmids comprising a CMV promoter operably linked to the 15H12/19D12 LCC, LCD, LCE, LCF or to the 15H12/19D12 HCA or HCB have been deposited at the American Type Culture Collection (ATCC); 10801 University Boulevard; Manassas, Va. 20110-2209 on May 21, 2003. The deposit names and the ATCC accession numbers for the plasmids are set forth below:

(1) CMV promoter-15H12/19D12 HCA (γ4)—

[0096] Deposit name: “15H12/19D12 HCA (γ4)”
[0097] ATCC accession No.: PTA-5214

(2) CMV promoter-15H12/19D12 HCB (γ4)—

[0098] Deposit name: “15H12/19D12 HCB (γ4)”
[0099] ATCC accession No.: PTA-5215

(3) CMV promoter-15H12/19D12 HCA (γ1)—

[0100] Deposit name: “15H12/19D12 HCA (γ1)”;
[0101] ATCC accession No.: PTA-5216

(4) CMV promoter-15H12/19D12 LCC (κ)—

[0102] Deposit name: “15H12/19D12 LCC (κ)”;
[0103] ATCC accession No.: PTA-5217

(5) CMV promoter-15H12/19D12 LCD (κ)—

[0104] Deposit name: “15H12/19D12 LCD (κ)”;
[0105] ATCC accession No.: PTA-5218

(6) CMV promoter-15H12/19D12 LCE (κ)—

[0106] Deposit name: “15H12/19D12 LCE (κ)”;
[0107] ATCC accession No.: PTA-5219

(7) CMV promoter-15H12/19D12 LCF (κ)—

[0108] Deposit name: “15H12/19D12 LCF (κ)”;
[0109] ATCC accession No.: PTA-5220
[0110] All restrictions on access to the plasmids deposited in ATCC will be removed upon grant of a patent. In an embodiment of the present invention, an anti-IGF1R antibody or antigen-binding fragment thereof of the invention comprises any of the CDRs or Ig heavy or light chains or variable regions thereof in any of PTA-5214-PTA-5220. In an embodiment of the invention, the antibody comprises a light chain encoded by the plasmid deposited under number PTA-5220 and a heavy chain encoded by the plasmid deposited under number PTA-5214 or PTA-5216.
[0111] In an embodiment, an antibody that binds “specifically” to human IGF1R binds with Kd of about 1.28×10−10 M or less by Biacore measurement or with a Kd of about 2.05×10−12 or less by KinExA measurement.
[0112] In an embodiment of the invention, an IGF1R inhibitory agent that can be administered to a patient in a method according to the invention comprises any light chain immunoglobulin and/or a heavy chain immunoglobulin as set forth in Published International Application No. WO 2002/53596 which is herein incorporated by reference in its entirety. For example, in an embodiment, the antibody comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 6, 10, 14, 18, 22, 47 and 51 as set forth in WO 2002/53596 and/or a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 8, 12, 16, 20, 24, 45 and 49 as set forth in WO 2002/53596.
[0113] In an embodiment of the invention, an IGF1R inhibitory agent that can be administered to a patient in a method according to the invention comprises any light chain immunoglobulin and/or a heavy chain immunoglobulin as set forth in Published International Application No. WO 2003/59951 which is herein incorporated by reference in its entirety. For example, in an embodiment, the antibody comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 54, 61 and 65 as set forth in WO 2003/59951 and/or a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 69, 75, 79 and 83 as set forth in WO 2003/59951.
[0114] In an embodiment of the invention, an IGF1R inhibitory agent that can be administered to a patient in a method according to the invention comprises any light chain immunoglobulin and/or a heavy chain immunoglobulin as set forth in Published International Application No. WO 2004/83248 which is herein incorporated by reference in its entirety. For example, in an embodiment, the antibody comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141 and 143 as set forth in WO 2004/83248 and/or a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140 and 142 as set forth in WO 2004/83248.
[0115] In an embodiment of the invention, an IGF1R inhibitory agent that can be administered to a patient in a method according to the invention comprises any light chain immunoglobulin and/or a heavy chain immunoglobulin as set forth in Published International Application No. WO 2003/106621 which is herein incorporated by reference in its entirety. For example, in an embodiment, the antibody comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 8-12, 58-69, 82-86, 90, 94, 96, 98, as set forth in WO 2003/106621 and/or a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 7, 13, 70-81, 87, 88, 92 as set forth in WO 2003/106621.
[0116] In an embodiment of the invention, an IGF1R inhibitory agent that can be administered to a patient in a method according to the invention comprises any light chain immunoglobulin and/or a heavy chain immunoglobulin as set forth in Published International Application No. WO 2004/87756 which is herein incorporated by reference in its entirety. For example, in an embodiment, the antibody comprises a light chain variable region comprising an amino acid sequence of SEQ ID NO: 2 as set forth in WO 2004/87756 and/or a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 1 as set forth in WO 2004/87756.
[0117] Furthermore, the scope of the present invention comprises any antibody or antibody fragment comprising one or more CDRs and/or framework regions of any of the light chain immunoglobulin or heavy chain immunoglobulins set forth in WO 2002/53596; WO 2003/59951; WO 2004/83248; WO 2003/106621 or WO 2004/87756 as identified by any of the methods set forth in Chothia et al., J. Mol. Biol. 186:651-663 (1985); Novotny and Haber, Proc. Natl. Acad. Sci. USA 82:4592-4596 (1985) or Kabat, E. A. et al., Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, Md., (1987)).
[0118] In an embodiment of the invention, anti-IGF1R antibody is produced by a hybridoma that is deposited at the American Type Culture Collection under deposit no. PTA-2792, PTA-2788, PTA-2790, PTA-2791, PTA-2789 or PTA-2793.
[0119] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises an immunoglobulin heavy chain variable region comprising an amino acid sequence selected from the group consisting of:
[0120] 
[00002] [TABLE-US-00002]
  (SEQ ID NO: 13)  
  1   grlgqawrsl rlscaasgft fsdyymswir qapgkglewv syisssgstr  
  51   dyadsvkgrf tisrdnakns lylqmnslra edtavyycvr dgvettfyyy
  101   yygmdvwgqg ttvtvssast kgpsvfplap csrstsesta algclvkdyf
  151   pepvtvswns galtsgvhtf psca
 
  (SEQ ID NO: 14)  
  1   vqllesgggl vqpggslrls ctasgftfss yamnwvrqap gkglewvsai  
  51   sgsggttfya dsvkgrftis rdnsrttlyl qmnslraedt avyycakdlg
  101   wsdsyyyyyg mdvwgqgttv tvss
 
  (SEQ ID NO: 15)  
  1   gpglvkpset lsltctvsgg sisnyywswi rqpagkglew igriytsgsp  
  51   nynpslksrv tmsvdtsknq fslklnsvta adtavyycav tifgvviifd
  101   ywgqgtlvtv ss
 
  (SEQ ID NO: 16)  
  1   evqllesggg lvqpggslrl scaasgftfs syamswvrqa pgkglewvsa  
  51   isgsggityy adsvkgrfti srdnskntly lqmnslraed tavyycakdl
  101   gygdfyyyyy gmdvwgqgtt vtvss
 
  (SEQ ID NO: 17)  
  1   pglvkpsetl sltctvsggs issyywswir qppgkglewi gyiyysgstn  
  51   ynpslksrvt isvdtsknqf slklssvtaa dtavyycart ysssfyyygm
  101   dvwgqgttvt vss
 
  (SEQ ID NO: 18)  
  1   evqllesggg lvqpggslrl scaasgftfs syamswvrqa pgkglewvsg  
  51   itgsggstyy adsvkgrfti srdnskntly lqmnslraed tavyycakdp
  101   gttvimswfd pwgqgtlvtv ss
[0121] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises an immunoglobulin light chain variable region comprising an amino acid sequence selected from the group consisting of:
[0122] 
[00003] [TABLE-US-00003]
  (SEQ ID NO: 19)  
  1   asvgdrvtft crasqdirrd lgwyqqkpgk apkrliyaas rlqsgvpsrf  
  51   sgsgsgteft ltisslqped fatyyclqhn nyprtfgqgt eveiirtvaa
  101   psvfifppsd eqlksgtasv vcllnnfypr eakvqw
 
  (SEQ ID NO: 20)  
  1   diqmtqfpss lsasvgdrvt itcrasqgir ndlgwyqqkp gkapkrliya  
  51   asrlhrgvps rfsgsgsgte ftltisslqp edfatyyclq hnsypcsfgq
  101   gtkleik
 
  (SEQ ID NO: 21)  
  1   sslsasvgdr vtftcrasqd irrdlgwyqq kpgkapkrli yaasrlqsgv  
  51   psrfsgsgsg teftltissl qpedfatyyc lqhnnyprtf gqgteveiir
 
  (SEQ ID NO: 22)  
  1   diqmtqspss lsasvgdrvt itcrasqgir sdlgwfqqkp gkapkrliya  
  51   asklhrgvps rfsgsgsgte ftltisrlqp edfatyyclq hnsypltfgg
  101   gtkveik
 
  (SEQ ID NO: 23)  
  1   gdrvtitcra sqsistflnw yqqkpgkapk llihvasslq ggvpsrfsgs  
  51   gsgtdftlti sslqpedfat yycqqsynap ltfgggtkve ik
 
  (SEQ ID NO: 24)  
  1   ratlscrasq svrgrylawy qqkpgqaprl liygassrat gipdrfsgsg  
  51   sgtdftltis rlepedfavf ycqqygsspr tfgqgtkvei k
[0123] In an embodiment of the invention, the anti-IGF1R antibody comprises a light chain immunoglobulin, or a mature fragment thereof (i.e., lacking signal sequence), or variable region thereof, comprising the amino acid sequence of:
[0124] 
[00004] [TABLE-US-00004]
  (SEQ ID NO: 25)  
  1mdmrvpaqll gllllwfpga rcdiqmtqsp sslsasvgdr vtitcrasqg  
  51irndlgwyqq kpgkapkrli yaasslgsgv psrfsgsgsg teftltissl
  101qpedfatyyc lqhnsypwtf gqgtkveikr tvaapsvfif ppsdeqlksg
  151   tasvvcllnn fypreakvqw kvdnalqsgn sqesvteqds kdstyslsst
  201   ltlskadyek hkvyacevth qglsspvtks fnrgec;
 
  (SEQ ID NO: 26)  
  1mdmrvpaqll gllllwfpga rcdiqmtqsp sslsasvgdr vtftcrasqd  
  51irrdlgwyqq kpgkapkrli yaasrlqsgv psrfsgsgsg teftltissl
  101qpedfatyyc lqhnnyprtf gqgteveiir tvaapsvfif ppsdeqlksg
  151   tasvvcllnn fypreakvqw kvdnalqsgn sqesvteqds kdstyslsst
  201   ltlskadyek hkvyacevth qglsspvtks fnrgec;
 
  (SEQ ID NO: 27)  
  1mdmrvpaqll gllllwfpga rcdiqmtqsp sslsasvgdr vtitcrasqg  
  51irndlgwyqq kpgkapkrli yaasslqsgv psrfsgsgsg teftltissl
  101qpedfatyyc lqhnsypytf gggtkleikr tvaapsvfif ppsdeqlksg
  151   tasvvcllnn fypreakvqw kvdnalqsgn sqesvteqds kdstyslsst
  201   ltlskadyek hkvyacevth qglsspvtks fnrgec;
  or
 
  (SEQ ID NO: 28)  
  1mdmrvpaqll gllllwfpga rcdiqmtqfp sslsasvgdr vtitcrasqg  
  51irndlgwyqq kpgkapkrli yaasrlhrgv psrfsgsgsg teftltissl
  101qpedfatyyc lqhnsypcsf gggtkleikr tvaapsvfif ppsdeqlksg
  151   tasvvcllnn fypreakvqw kvdnalqsgn sqesvteqds kdstyslsst
  201   ltlskadyek hkvyacevth qglsspvtks fnrgec.

In an embodiment of the invention, the signal sequence is amino acids 1-22 of SEQ ID NOs: 25-28. In an embodiment of the invention, the mature variable region is underscored.
[0125] In an embodiment of the invention, the anti-IGF1R antibody comprises a heavy chain immunoglobulin or a mature fragment thereof (i.e., lacking signal sequence), or a variable region thereof, comprising the amino acid sequence of:
[0126] 
[00005] [TABLE-US-00005]
  (SEQ ID NO: 29)  
  1mefglswvfl vaiikgvqcq vqlvesgggl vkpggslrls caasgftfsd  
  51yymswirqap gkglewvsyi sssgstiyya dsvkgrftis rdnaknslyl
  101qmnslraedt avyycarvlr flewllyyyy yygmdvwgqg ttvtvssast
  151   kgpsvfplap csrstsesta algclvkdyf pepvtvswns galtsgvhtf
  201   pavlqssgly slssvvtvps snfgtqtytc nvdhkpsntk vdktverkcc
  251   vecppcpapp vagpsvflfp pkpkdtlmis rtpevtcvvv dvshedpevq
  301   fnwyvdgvev hnaktkpree qfnstfrvvs vltvvhqdwl ngkeykckvs
  351   nkglpapiek tisktkgqpr epqvytlpps reemtknqvs ltclvkgfyp
  401   sdiavewesn gqpennyktt ppmldsdgsf flyskltvdk srwqqgnvfs
  451   csvmhealhn hytqkslsls pgk;
 
  (SEQ ID NO: 30)  
  1mefglswvfl vaiikgvqcq aqlvesgggl vkpggslrls caasgftfsd  
  51yymswirqap gkglewvsyi sssgstrdya dsvkgrftis rdnaknslyl
  101qmnslraedt avyycvrdgv ettfyyyyyg mdvwgqgttv tvssastkgp
  151   svfplapcsr stsestaalg clvkdyfpep vtvswnsgal tsgvhtfpav
  201   lqssglysls svvtvpssnf gtqtytcnvd hkpsntkvdk tverkccvec
  251   ppcpappvag psvflfppkp kdtlmisrtp evtcvvvdvs hedpevqfnw
  301   yvdgvevhna ktkpreeqfn stfrvvsvlt vvhqdwlngk eykckvsnkg
  351   lpapiektis ktkgqprepq vytlppsree mtknqvsltc lvkgfypsdi
  401   avewesngqp ennykttppm ldsdgsffly skltvdksrw qqgnvfscsv
  451   mhealhnhyt qkslslspgk;
 
  (SEQ ID NO: 31)  
  1mefglswlfl vailkgvqce vqllesgggl vqpggslrls caasgftfss  
  51yamswvrqap gkglewvsai sgsggstyya dsvkgrftis rdnskntlyl
  101qmnslraedt avyycakgys sgwyyyyyyg mdvwgqgttv tvssastkgp
  151   svfplapcsr stsestaalg clvkdyfpep vtvswnsgal tsgvhtfpav
  201   lqssglysls svvtvpssnf gtqtytcnvd hkpsntkvdk tverkccvec
  251   ppcpappvag psvflfppkp kdtlmisrtp evtcvvvdvs hedpevqfnw
  301   yvdgvevhna ktkpreeqfn stfrvvsvlt vvhqdwlngk eykckvsnkg
  351   lpapiektis ktkgqprepq vytlppsree mtknqvsltc lvkgfypsdi
  401   avewesngqp ennykttppm ldsdgsffly skltvdksrw qqgnvfscsv
  451   mhealhnhyt qkslslspgk;
  or
 
  (SEQ ID NO: 32)  
  1mefglswlfl vailkgvqce vqllesgggl vqpggslrls ctasgftfss  
  51yamnwvrqap gkglewvsai sgsggttfya dsvkgrftis rdnsrttlyl
  101qmnslraedt avyycakdlg wsdsyyyyyg mdvwgqgttv tvssastkgp
  151   svfplapcsr stsestaalg clvkdyfpep vtvswnsgal tsgvhtfpav
  201   lqssglysls svvtvpssnf gtqtytcnvd hkpsntkvdk tverkccvec
  251   ppcpappvag psvflfppkp kdtlmisrtp evtcvvvdvs hedpevqfnw
  301   yvdgvevhna ktkpreeqfn stfrvvsvlt vvhqdwlngk eykckvsnkg
  351   lpapiektis ktkgqprepq vytlppsree mtknqvsltc lvkgfypsdi
  401   avewesngqp ennykttppm ldsdgsffly skltvdksrw qqgnvfscsv
  451   mhealhnhyt qkslslspgk.

In an embodiment of the invention, the signal sequence is amino acids 1-19 of SEQ ID NOs: 29-32. In an embodiment of the invention, the mature variable region is underscored.
[0127] In an embodiment of the invention, the anti-IGF1R antibody comprises a light chain variable region comprising the amino acid sequence of any of SEQ ID NOs: 19-24 paired with a heavy chain variable region comprising an amino acid sequence of any of SEQ ID NOs: 13-18, respectively. In an embodiment of the invention, the anti-IGF1R antibody comprises a mature light chain variable region comprising an amino acid sequence of any of SEQ ID NOs: 25 or 26 paired with a heavy chain variable region comprising an amino acid sequence of any of SEQ ID NOs: 29 or 30. In an embodiment of the invention, the anti-IGF1R antibody comprises a mature light chain variable region comprising an amino acid sequence of any of SEQ ID NOs: 27 or 28 paired with a heavy chain variable region comprising an amino acid sequence of any of SEQ ID NOs: 31 or 32.
[0128] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises an immunoglobulin heavy chain or mature fragment or variable region of 2.12.1 fx (SEQ ID NO: 33) (in an embodiment of the invention, the leader sequence is underscored):
[0129] 
[00006] [TABLE-US-00006]
  1mefglswvfl vaiikgvqcq vqlvesgggl vkpggslrls caasgftfsd  
 
  51   yymswirqap gkglewvsyi sssgstrdya dsvkgrftis rdnaknslyl
 
  101   qmnslraedt avyycardgv ettfyyyyyg mdvwgqgttv tvssastkgp
 
  151   svfplapcsr stsestaalg clvkdyfpep vtvswnsgal tsgvhtfpav
 
  201   lqssglysls svvtvpssnf gtqtytcnvd hkpsntkvdk tverkccvec
 
  251   ppcpappvag psvflfppkp kdtlmisrtp evtcvvvdvs hedpevqfnw
 
  301   yvdgvevhna ktkpreeqfn stfrvvsvlt vvhqdwlngk eykckvsnkg
 
  351   lpapiektis ktkgqprepq vytlppsree mtknqvsltc lvkgfypsdi
 
  401   avewesngqp ennykttppm ldsdgsffly skltvdksrw qqgnvfscsv
 
  451   mhealhnhyt qkslslspgk
[0130] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises mature immunoglobulin heavy chain variable region 2.12.1 fx (amino acids 20-144 or SEQ ID NO: 33; SEQ ID NO: 34):
[0131] 
[00007] [TABLE-US-00007]
  q vqlvesgggl vkpggslrls caasgftfsd yymswirqap gkglewvsyi sssgstrdya  
 
  dsvkgrftis rdnaknslyl qmnslraedt avyycardgv ettfyyyyyg mdvwgqgttv tvss
[0132] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises an immunoglobulin light chain or mature fragment or variable region 2.12.1 fx (SEQ ID NO: 35) (in an embodiment of the invention, the leader sequence is underscored):
[0133] 
[00008] [TABLE-US-00008]
  1mdmrvpaqll gllllwfpga rcdiqmtqsp sslsasvgdr vtitcrasqd  
 
  51   irrdlgwyqq kpgkapkrli yaasrlqsgv psrfsgsgsg teftltissl
 
  101   qpedfatyyc lqhnnyprtf gqgtkveikr tvaapsvfif ppsdeqlksg
 
  151   tasvvcllnn fypreakvqw kvdnalqsgn sqesvteqds kdstyslsst
 
  201   ltlskadyek hkvyacevth qglsspvtks fnrgec
[0134] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises mature immunoglobulin light chain variable region 2.12.1 fx (amino acids 23-130 of SEQ ID NO: 35; SEQ ID NO: 36):
[0135] 
[00009] [TABLE-US-00009]
  diqmtqsp sslsasvgdr vtitcrasqd irrdlgwyqq kpgkapkrli yaasrlqsgv  
 
  psrfsgsgsg teftltissl qpedfatyyc lqhnnyprtf gqgtkveikr
[0136] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises a humanized 7C10 immunoglobulin light chain variable region; version 1 (SEQ ID NO: 37):
[0137] 
[00010] [TABLE-US-00010]
  1   dvvmtqspls lpvtpgepas iscrssqsiv hsngntylqw ylqkpgqspq  
 
  51   lliykvsnrl ygvpdrfsgs gsgtdftlki srveaedvgv yycfqgshvp
 
  101   wtfgqgtkve ik
[0138] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises humanized 7C10 immunoglobulin light chain variable region; version 2 (SEQ ID NO: 38):
[0139] 
[00011] [TABLE-US-00011]
  1   divmtqspls lpvtpgepas iscrssqsiv hsngntylqw ylqkpgqspq  
 
  51   lliykvsnrl ygvpdrfsgs gsgtdftlki srveaedvgv yycfqgshvp
 
  101   wtfgqgtkve ik
[0140] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises a humanized 7C10 immunoglobulin heavy chain variable region; version 1 (SEQ ID NO: 39):
[0141] 
[00012] [TABLE-US-00012]
  1   qvqlqesgpg lvkpsetlsl tctvsgysit ggylwnwirq ppgkglewmg  
 
  51   yisydgtnny kpslkdriti srdtsknqfs lklssvtaad tavyycaryg
 
  101   rvffdywgqg tlvtvss
[0142] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises the humanized 7C10 immunoglobulin heavy chain variable region; version 2 (SEQ ID NO: 40):
[0143] 
[00013] [TABLE-US-00013]
  1   qvqlqesgpg lvkpsetlsl tctvsgysit ggylwnwirq ppgkglewig  
 
  51   yisydgtnny kpslkdrvti srdtsknqfs lklssvtaad tavyycaryg
 
  101   rvffdywgqg tlvtvss
[0144] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises the humanized 7C10 immunoglobulin heavy chain variable region; version 3 (SEQ ID NO: 41):
[0145] 
[00014] [TABLE-US-00014]
  1   qvqlqesgpg lvkpsetlsl tctvsgysis ggylwnwirq ppgkglewig  
 
  51   yisydgtnny kpslkdrvti svdtsknqfs lklssvtaad tavyycaryg
 
  101   rvffdywgqg tlvtvss
[0146] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises A12 immunoglobulin heavy chain variable region (SEQ ID NO: 42):
[0147] 
[00015] [TABLE-US-00015]
  1   evqlvqsgae vkkpgssvkv sckasggtfs syaiswvrqa pgqglewmgg  
 
  51   iipifgtany aqkfqgrvti tadkststay melsslrsed tavyycarap
 
  101   lrflewstqd hyyyyymdvw gkgttvtvss
[0148] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises A12 immunoglobulin light chain variable region (SEQ ID NO: 43):
[0149] 
[00016] [TABLE-US-00016]
  1   sseltqdpav svalgqtvri tcqgdslrsy yaswyqqkpg qapvlviygk  
  51   nnrpsgipdr fsgsssgnta sltitgaqae deadyycnsr dnsdnrlifg
  101   ggtkltvls

or (SEQ ID NO: 105):
[0150] 
[00017] [TABLE-US-00017]
 
  1   sseltqdpav   svalgqtvri   tcqgdslrsy   yatwyqqkpg   qapilviyge  
 
  51   nkrpsgipdr   fsgsssgnta   sltitgaqae   deadyycksr   dgsgqhlvfg
 
  101   ggtkltvlg
 
[0151] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises 1A immunoglobulin heavy chain variable region (SEQ ID NO: 44):
[0152] 
[00018] [TABLE-US-00018]
  1   evqlvqsggg lvhpggslrl scagsgftfr nyamywvrqa pgkglewvsa  
 
  51   igsgggtyya dsvkgrftis rdnaknslyl qmnslraedm avyycarapn
 
  101   wgsdafdiwg qgtmvtvss;

optionally including one or more of the following mutations: R30, S30, N31, S31, Y94, H94, D104, E104.
[0153] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises 1A immunoglobulin light chain variable region (SEQ ID NO: 45):
[0154] 
[00019] [TABLE-US-00019]
  1   diqmtqspss lsasvgdrvt itcrasqgis swlawyqqkp ekapksliya  
 
  51   asslqsgvps rfsgsgsgtd ftltisslqp edfatyycqq ynsypptfgp
 
  101   gtkvdik;

optionally including one or more of the following mutations: P96, 196, P100, Q100, R103, K103, V104, L104, D105, E105
[0155] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises single chain antibody (fv) 8A1 (SEQ ID NO: 46):
[0156] 
[00020] [TABLE-US-00020]
  1   evqlvqsgae vkkpgeslti sckgpgynff nywigwvrqm pgkglewmgi  
 
  51   iyptdsdtry spsfqgqvti svdksistay lqwsslkasd tamyycarsi
 
  101   rycpggrcys gyygmdvwgq gtmvtvssgg ggsggggsgg ggsseltqdp
 
  151   avsvalgqtv ritcqgdslr syyaswyqqk pgqapvlviy gknnrpsgip
 
  201   drfsgsssgn tasltitgaq aedeadyycn srdssgnhvv fgggtkltvl
 
  251   g
[0157] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises single chain antibody (fv) 9A2 (SEQ ID NO: 47):
[0158] 
[00021] [TABLE-US-00021]
  1   qvqlvqsgae vrkpgasvkv scktsgytfr nydinwvrqa pgqglewmgr  
 
  51   isghygntdh aqkfqgrftm tkdtststay melrsltfdd tavyycarsq
 
  101   wnvdywgrgt lvtvssgggg sggggsgggg salnfmltqp hsvsespgkt
 
  151   vtisctrssg siasnyvqwy qqrpgssptt vifednrrps gvpdrfsgsi
 
  201   dtssnsaslt isglktedea dyycqsfdst nlvvfgggtk vtvlg
[0159] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises single chain antibody (fv) 11A4 (SEQ ID NO: 48):
[0160] 
[00022] [TABLE-US-00022]
  1   evqllesggg lvqpggslrl scaasgftfs syamswvrqa pgkglewvsa  
 
  51   isgsggstyy adsvkgrfti srdnskntly lqmnslraed tavyycassp
 
  101   yssrwysfdp wgqgtmvtvs sggggsgggg sggggsalsy eltqppsvsv
 
  151   spgqtatitc sgddlgnkyv swyqqkpgqs pvlviyqdtk rpsgiperfs
 
  201   gsnsgniatl tisgtqavde adyycqvwdt gtvvfgggtk ltvlg
[0161] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises single chain antibody (fv) 7A4 (SEQ ID NO: 49):
[0162] 
[00023] [TABLE-US-00023]
  1   evqlvqsgae vkkpgeslti sckgsgynff nywigwvrqm pgkdlewmgi  
 
  51   iyptdsdtry spsfqgqvti svdksistay lqwsslkasd tamyycarsi
 
  101   rycpggrcys gyygmdvwgq gtmvtvssgg gssggggsgg ggsseltqdp
 
  151   avsvalgqtv ritcrgdslr nyyaswyqqk pgqapvlviy gknnrpsgip
 
  201   drfsgsssgn tasltitgaq aedeadyycn srdssgnhmv fgggtkltvl
 
  251   g
[0163] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises single chain antibody (fv) 11A1 (SEQ ID NO: 50):
[0164] 
[00024] [TABLE-US-00024]
  1   evqlvesggg vvqpgrslrl scaasgftfs dfamhwvrqi pgkglewlsg  
 
  51   lrhdgstayy agsvkgrfti srdnsrntvy lqmnslraed tatyycvtgs
 
  101   gssgphafpv wgkgtlvtvs sggggsgggg sggggsalsy vltqppsasg
 
  151   tpgqrvtisc sgsnsnigty tvnwfqqlpg tapklliysn nqrpsgvpdr
 
  201   fsgsksgtsa slaisglqse deadyycaaw ddslngpvfg ggtkvtvlg
[0165] In an embodiment of the invention, an anti-IGF1R antibody of the invention comprises single chain antibody (fv) 7A6 (SEQ ID NO: 51)
[0166] 
[00025] [TABLE-US-00025]
  1   evqlvqsgae vkkpgeslti sckgsgynff nywigwvrqm pgkglewmgi  
 
  51   iyptdsdtry spsfqgqvti svdksistay lqwsslkasd tamyycarsi
 
  101   rycpggrcys gyygmdvwgq gtlvtvssgg ggsggggsgg ggsseltqdp
 
  151   avsvalgqtv ritcqgdslr syytnwfqqk pgqapllvvy aknkrpsgip
 
  201   drfsgsssgn tasltitgaq aedeadyycn srdssgnhvv fgggtkltvl
 
  251   g
[0167] In an embodiment of the invention, an anti-IGF1R antibody or an antigen-binding fragment thereof (e.g., a heavy chain or light chain immunoglobulin) of the invention comprises one or more complementarity determing regions (CDR) selected from the group consisting of:
[0168] 
[00026] [TABLE-US-00026]
    sywmh;   (SEQ ID NO: 52)  
   
    einpsngrtnynekfkr;   (SEQ ID NO: 53)
   
    grpdyygsskwyfdv;   (SEQ ID NO: 54)
   
    rssqsivhsnvntyle;   (SEQ ID NO: 55)
   
    kvsnrfs;   (SEQ ID NO: 56)
    and
   
    fqgshvppt.   (SEQ ID NO: 57)
[0169] In an embodiment of the invention, an anti-IGF1R antibody or an antigen-binding fragment thereof of the invention comprises a heavy chain immunoglobulin variable region selected from the group consisting of:
[0170] 
[00027] [TABLE-US-00027]
  (SEQ ID NO: 58)  
  1   qvqlvqsgae vvkpgasvkl sckasgytft sywmhwvkqr pgqglewige  
  51   inpsngrtny nqkfqgkatl tvdkssstay mqlssltsed savyyfargr
  101   pdyygsskwy fdvwgqgttv tvs;
 
  (SEQ ID NO: 59)  
  1   qvqfqqsgae lvkpgasvkl sckasgytft sylmhwikqr pgrglewigr  
  51   idpnnvvtkf nekfkskatl tvdkpsstay melssltsed savyycarya
  101   ycrpmdywgq gttvtvss;
 
  (SEQ ID NO: 60)  
  1   qvqlqqsgae lvkpgasvkl sckasgytft sywmhwvkqr pgqglewige  
  51   inpsngrtny nekfkrkatl tvdkssstay mqlssltsed savyyfargr
  101   pdyygsskwy fdvwgagttv tvs;
 
  (SEQ ID NO: 61)  
  1   qvqlqqsgae lmkpgasvki sckatgytfs sfwiewvkqr pghglewige  
  51   ilpgsggthy nekfkgkatf tadkssntay mqlssltsed savyycargh
  101   syyfydgdyw gqgtsvtvss;
 
  (SEQ ID NO: 62)  
  1   qvqlqqpgsv lvrpgasvkl sckasgytft sswihwakqr pgqglewige  
  51   ihpnsgntny nekfkgkatl tvdtssstay vdlssltsed savyycarwr
  101   ygspyyfdyw gqgttltvss;
 
  (SEQ ID NO: 63)  
  1   qvqlqqpgae lvkpgasvkl sckasgytft sywmhwvkqr pgrglewigr  
  51   idpnsggtky nekfkskatl tvdkpsstay mqlssltsed savyycaryd
  101   yygssyfdyw gqgttltvss;
 
  (SEQ ID NO: 64)  
  1   qvqlvqsgae vvkpgasvkl sckasgytft sywmhwvkqr pgqglewige  
  51   inpsngrtny nqkfqgkatl tvdkssstay mqlssltsed savyyfargr
  101   pdyygsskwy fdvwgqgttv tvs;
 
  (SEQ ID NO: 65)  
  1   qvqlqqsgae lvkpgasvkl sckasgytft sywmhwvkqr pgqglewige  
  51   inpsngrtny nekfkrkatl tvdkssstay mqlssltsed savyyfargr
  101   pdyygsskwy fdvwgagttv tvss;
 
  (SEQ ID NO: 66)  
  1   qvqlvqsgae vvkpgasvkl sckasgytft sywmhwvkqr pgqglewige  
  51   inpsngrtny nqkfqgkatl tvdkssstay mqlssltsed savyyfargr
  101   pdyygsskwy fdvwgqgttv tvss;
 
  (SEQ ID NO: 67)  
  1   qvqlqqsgae lvkpgasvkl sckasgytft sywmhwvkqr pgrglewigr  
  51   idpnsggtky nekfkskatl tvdkpsstay mqlssltsed savyycaryd
  101   yygssyfdyw gqgttvtvss;
 
  (SEQ ID NO: 68)  
  1   qiqlqqsgpe lvrpgasvki sckasgytft dyyihwvkqr pgeglewigw  
  51   iypgsgntky nekfkgkatl tvdtssstay mqlssltsed savyfcargg
  101   kfamdywgqg tsvtvss;
 
  (SEQ ID NO: 69)  
  1   qvqlqqsgae lvkpgasvkl sckasgytft sywmhwvkqr pgqglewige  
  51   inpsngrtny nekfkrkatl tvdkssstay mqlssltsed savyyfargr
  101   pdyygsskwy fdvwgagttv tvss;
 
  (SEQ ID NO: 70)  
  1   qiqlqqsgpe lvkpgasvki sckasgytft dyyinwmkqk pgqglewigw  
  51   idpgsgntky nekfkgkatl tvdtssstay mqlssltsed tavyfcarek
  101   ttyyyamdyw gqgtsvtvsa;
 
  (SEQ ID NO: 71)  
  1   vqlqqsgael mkpgasvkis ckasgytfsd ywiewvkqrp ghglewigei  
  51   lpgsgstnyh erfkgkatft adtssstaym qlnsltseds gvyyclhgny
  101   dfdgwgqgtt ltvss;
  and  
 
  (SEQ ID NO: 72)  
  1   qvqllesgae lmkpgasvki sckatgytfs sfwiewvkqr pghglewige  
  51   ilpgsggthy nekfkgkatf tadkssntay mqlssltsed savyycargh
  101   syyfydgdyw gqgtsvtvss;
[0171] and/or a light chain immunoglobulin variable region selected from the group consisting of:
[0172] 
[00028] [TABLE-US-00028]
  (SEQ ID NO: 73)  
  1   dvlmtqipvs lpvslgdqas iscrssqiiv hnngntylew ylqkpgqspq  
  51   lliykvsnrf sgvpdrfsgs gsgtdftlki srveaedlgv yycfqgshvp
  101   ftfgsgtkle ikr;
 
  (SEQ ID NO: 74)  
  1   dvlmtqtpls lpvslgdpas iscrssqsiv hsnvntylew ylqkpgqspk  
  51   lliykvsnrf sgvpdrfsgs gagtdftlri srveaedlgi yycfqgshvp
  101   ptfgggtkle ikr;
 
  (SEQ ID NO: 75)  
  1   dvlmtqtpls lpvslgdpas iscrssqsiv hsnvntylew ylqkpgqspr  
  51   lliykvsnrf sgvpdrfsgs gagtdftlri srveaedlgi yycfqgshvp
  101   ptfgggtkle ikr;
 
  (SEQ ID NO: 76)  
  1   dvlmtqtpls lpvslgdpas iscrssqsiv hsnvntylew ylqkpgqspk  
  51   lliykvsnrf sgvpdrfsgs gagtdftlri srveaedlgi yycfqgshvp
  101   ptfgggtkle ikr;
 
  (SEQ ID NO: 77)  
  1   dvlmtqtpls lpvslgdpas iscrssqsiv hsnvntylew ylqkpgqspr  
  51   lliykvsnrf sgvpdrfsgs gagtdftlri srveaedlgi yycfqgshvp
  101   ptfgggtkle ikr;
 
  (SEQ ID NO: 78)  
  1   dvlmtqtpls lpvslgdqas iscrssqxiv hsngntylew ylqkpgqspk  
  51   lliykvsnrf sgvpdrfsgs gsgtdftlki srveaedlgv yycfqgshvp
  101   xtfgggtkle ikr;
 
  (SEQ ID NO: 79)  
  1   dvvmtqtpls lpvslgdpas iscrssqsiv hsnvntylew ylqkpgqspk  
  51   lliykvsnrf sgvpdrfsgs gagtdftlri srveaedlgi yycfqgshvp
  101   ptfgggtkle ikr;
 
  (SEQ ID NO: 80)  
  1   dvvmtqtpls lpvslgdpas iscrssqsiv hsnvntylew ylqkpgqspr  
  51   lliykvsnrf sgvpdrfsgs gagtdftlri srveaedlgi yycfqgshvp
  101   ptfgggtkle ikr;
 
  (SEQ ID NO: 81)  
  1   dvlmtqtpls lpvslgdpas iscrssqsiv hsnvntylew ylqkpgqspr  
  51   lliykvsnrf sgvpdrfsgs gagtdftlri srveaedlgi yycfqgshvp
  101   ptfgggtkle ikr;
 
  (SEQ ID NO: 82)  
  1   dvlmtqipvs lpvslgdqas iscrssqiiv hnngntylew ylqkpgqspq  
  51   lliykvsnrf sgvpdrfsgs gsgtdftlki srveaedlgv yycfqgshvp
  101   ftfgsgtkle ikr;
 
  (SEQ ID NO: 83)  
  1   dvlmtqtpls lpvslgdqas iscrfsqsiv hsngntylew ylqksgqspk  
  51   lliykvsnrf sgvpdrfsgs gsgtdftlki srveaedlgv yycfqgshvp
  101   rtfgggtkle ikr;
 
  (SEQ ID NO: 84)  
  1   dvlmtqtpls lpvslgdqas iscrssqsiv hsnvntylew ylqkpgqspk  
  51   lliykvsnrf sgvpdrfsgs gsgtdftlri srveaedlgi yycfqgshvp
  101   ptfgggtkle ikr;
 
  (SEQ ID NO: 85)  
  1   dvvmtqtpls lpvslgdpas iscrssqsiv hsnvntylew ylqkpgqspk  
  51   lliykvsnrf sgvpdrfsgs gagtdftlri srveaedlgi yycfqgshvp
  101   ptfgggtkle ikr;
 
  (SEQ ID NO: 86)  
  1   elvmtqtpls lpvslgdqas iscrssqtiv hsngdtyldw flqkpgqspk  
  51   lliykvsnrf sgvpdrfsgs gsgtdftlki srveaedlgv yycfqgshvp
  101   ptfgggtkle ikr;
 
  (SEQ ID NO: 87)  
  1   dvlmtqtpls lpvslgdpas iscrssqsiv hsnvntylew ylqkpgqspk  
  51   lliykvsnrf sgvpdrfsgs gagtdftlri srveaedlgi yycfqgshvp
  101   ptfgggtkle ikr;
 
  (SEQ ID NO: 88)  
  1   dvvmtqtpls lpvslgdpas iscrssqsiv hsnvntylew ylqkpgqspr  
  51   lliykvsnrf sgvpdrfsgs gagtdftlri srveaedlgi yycfqgshvp
  101   ptfgggtkle ikr;
 
  (SEQ ID NO: 89)  
  1   dvlmtqtpvs lsvslgdqas iscrssqsiv hstgntylew ylqkpgqspk  
  51   lliykisnrf sgvpdrfsgs gsgtdftlki srveaedlgv yycfqashap
  101   rtfgggtkle ikr;
 
  (SEQ ID NO: 90)  
  1   dvlmtqtpls lpvslgdqas isckssqsiv hssgntyfew ylqkpgqspk  
  51   lliykvsnrf sgvpdrfsgs gsgtdftlki srveaedlgv yycfqgship
  101   ftfgsgtkle ikr;
 
  (SEQ ID NO: 91)  
  1   dieltqtpls lpvslgdqas iscrssqsiv hsngntylew ylqkpgqspk  
  51   lliykvsnrf sgvpdrfsgs gsgtdftlki srveaedlgv yycfqgshvp
  101   ytfgggtkle ikr;
 
  (SEQ ID NO: 92)  
  1   dvlmtqtpls lpvslgdqas iscrssqsiv hsnvntylew ylqkpgqspk  
  51   lliykvsnrf sgvpdrfsgs gsgtdftlri srveaedlgi yycfqgshvp
  101   ptfgggtkle ikr;
 
  (SEQ ID NO: 93)  
  1   dvvmtqtpls lpvslgdpas iscrssqsiv hsnvntylew ylqkpgqspr  
  51   lliykvsnrf sgvpdrfsgs gagtdftlri srveaedlgi yycfqgshvp
  101   ptfgggtkle ikr;
 
  (SEQ ID NO: 94)  
  1   dvlmtqtpls lpvslgdqas iscrssqsiv hsnvntylew ylqkpgqspk  
  51   lliykvsnrf sgvpdrfsgs gsgtdftlri srveaedlgi yycfqgshvp
  101   ptfgggtkle ikr;
 
  (SEQ ID NO: 95)  
  1   dvvmtqtpls lpvslgdpas iscrssqsiv hsnvntylew ylqkpgqspk  
  51   lliykvsnrf sgvpdrfsgs gagtdftlri srveaedlgi yycfqgshvp
  101   ptfgggtkle ikr;
 
  (SEQ ID NO: 96)  
  1   dvlmtqtpls lpvslgdqas iscrsnqtil lsdgdtylew ylqkpgqspk  
  51   lliykvsnrf sgvpdrfsgs gsgtdftlki srveaedlgv yycfqgshvp
  101   ptfgggtkle ikr;
 
  (SEQ ID NO: 97)  
  1   dvlmtqtpls lpvslgdqas iscrssqtiv hsngntylew ylqkpgqspk  
  51   lliykvtnrf sgvpdrfsgs gsgtdftlki srveaedlgv yycfqgthap
  101   ytfgggtkle ikr;
  and  
 
  (SEQ ID NO: 98)  
  1   dvlmtqtpls lpvslgdqas iscrssqsiv hsngntylew ylqkpgqspk  
  51   lliysissrf sgvpdrfsgs gsgtdftlki srvqaedlgv yycfqgshvp
  101   ytfgggtkle ikr.
[0173] The scope of the present invention includes methods wherein a patient is administered an anti-insulin-like growth factor receptor-1 (IGF1R) antibody wherein the variable region of the antibody is linked to any immunoglobulin constant region. In an embodiment, the light chain variable region is linked to a κ chain constant region. In an embodiment, the heavy chain variable region is linked to a γ1, γ2, γ3 or γ4 chain constant region. Any of the immunoglobulin variable regions set forth herein, in embodiments of the invention, can be linked to any of the foregoing constant regions.
[0174] In an embodiment of the invention, an IGF1R inhibitory agent that can be administered to a patient in a method according to the invention is AEW-541 (NVP-AEW-541; NVP-AEW-541-NX-7):
[0175]  [see pdf for image]
(Novartis; East Hanover, N.J.; see WO 2002/92599);
[0176]  [see pdf for image]
(WO 2003/39538).
[0177] In an embodiment of the invention, an IGF1R inhibitory agent that can be administered to a patient in a method according to the invention is any IGF1R anti-sense nucleic acid. For example, in an embodiment, the anti-sense IGF1R nucleic acid is ATL-1101 (Antisense Therapeutics Ltd; Australia). In an embodiment, the IGF1R anti-sense nucleic acid comprises any of the following nucleotide sequences: 5′-ATCTCTCCGCTTCCTTTC-3′ (SEQ ID NO: 99), 5′-ATCTCTCCGCTTCCTTTC-3′ (SEQ ID NO: 100), 5′-ATCTCTCCGCTTCCTTTC-3′ (SEQ ID NO: 101) or any IGF1R antisense nucleic acid set forth in any of US Published Patent Application No. US20030096769; Published International Application No. WO 2003/100059; Fogarty et al., Antisense Nucleic Acid Drug Dev. 2002 December; 12(6):369-77; White et al., J Invest Dermatol. 2002 June; 118(6):1003-7; White et al., Antisense Nucleic Acid Drug Dev. 2000 June; 10(3):195-203; or Wraight et al., Nat Biotechnol. 2000 May; 18(5):521-6.
[0178] In an embodiment of the invention, an IGF1R inhibitory agent that can be administered to a patient in a method according to the invention is an anti-IGF-I or II antibody; for example, any antibody disclosed in WO 2003/93317 or EP00492552.
[0179] The scope of the present invention includes any kinase inhibitor compound set forth in published international applications WO 2004/030627 or WO 2004/030625. In an embodiment, the kinase inhibitor is (±)-4-[2-(3-chloro-4-fluoro-phenyl)-2-hydroxy-ethylamino]-3-[6-(imidazol-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one:
[0180]  [see pdf for image]
(optionally in combination with paclitaxel or with cetuximab).
[0181] In an embodiment of the invention, the IGR1R inhibitory agent is a soluble fragment of IGF1R (e.g., amino acids 30-902 of IGF1R) or siRNA (small interfering RNA) against IGF-1R.
[0182] In an embodiment, IGF1R comprises the amino acid sequence set forth under Genbank Accession No.: XM052648 or NM000612.
[0183] The present invention also includes embodiments wherein the patient receives both an IGF1R inhibitory agent in association with one or more other anti-cancer agents, including, but not limited to paclitaxel, thalidomide, docetaxel, gefitinib, temozolomide, lonafarnib, tipifarnib, letrozole, doxorubicin, cis-platin, oxaliplatin, camptothecan, topotecan, etoposide, vincristine, vinblastine, raloxifene, gemcitabine, retinoic acid, tamoxifen, trastuzumab, cetuximab or octreotide; or anti-cancer therapeutic procedures including, but not limited to, surgical tumorectomy or anti-cancer radiation therapy. The present invention further includes embodiment wherein two or more IGF1R inhibitory agents are administered in association with one another.
[0184] The term “in association” indicates that the components of the combinations of the invention can be formulated into a single composition for simultaneous delivery or formulated separately into two or more compositions (e.g., a kit). Furthermore, each component of a combination of the invention can be administered to a subject at a different time than when the other component is administered; for example, each administration may be given non-simultaneously at several intervals over a given period of time. Moreover, the separate components may be administered to a subject by the same or by a different route (e.g., orally, intravenously, intratumorally).

Generation of Antibodies

[0185] Any suitable method can be used to elicit an antibody with the desired biologic properties to inhibit IGF1R. It is desirable to prepare monoclonal antibodies (mAbs) from various mammalian hosts, such as mice, rodents, primates, humans, etc. Description of techniques for preparing such monoclonal antibodies may be found in, e.g., Stites, et al. (eds.) BASIC AND CLINICAL IMMUNOLOGY (4th ed.) Lange Medical Publications, Los Altos, Calif., and references cited therein; Harlow and Lane (1988) ANTIBODIES: A LABORATORY MANUAL CSH Press; Goding (1986) MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE (2d ed.) Academic Press, New York, N.Y. Thus, monoclonal antibodies may be obtained by a variety of techniques familiar to researchers skilled in the art. Typically, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell. See Kohler and Milstein (1976) Eur. J. Immunol. 6:511-519. Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods known in the art. See, e.g., Doyle, et al. (eds. 1994 and periodic supplements) CELL AND TISSUE CULTURE: LABORATORY PROCEDURES, John Wiley and Sons, New York, N.Y. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host. Alternatively, one may isolate DNA sequences which encode a monoclonal antibody or a binding fragment thereof by screening a DNA library from human B cells according, e.g., to the general protocol outlined by Huse, et al. (1989) Science 246:1275-1281. Modified antibodies can be generated, for example, by introducing mutations in DNA encoding an immunoglobulin chain, for example, by use of conventional recombinant biological techniques.
[0186] Other suitable techniques involve selection of libraries of antibodies in phage or similar vectors. See, e.g., Huse et al., Science 246:1275-1281 (1989); and Ward et al., Nature 341:544-546 (1989). The polypeptides and antibodies of the present invention may be used with or without modification, including chimeric or humanized antibodies. Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents teaching the use of such labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced, see Cabilly U.S. Pat. No. 4,816,567; and Queen et al. (1989) Proc. Nat'l Acad. Sci. USA 86:10029-10033; or made in transgenic mice, see Mendez et al. (1997) Nature Genetics 15:146-156. Further methods for producing chimeric, humanized and human antibodies are well known in the art. See, e.g., U.S. Pat. No. 5,530,101, issued to Queen et al, U.S. Pat. No. 5,225,539, issued to Winter et al, U.S. Pat. No. 4,816,397 issued to Boss et al, all of which are incorporated by reference in their entirety.

Tumor Analysis

[0187] The methods of the present method comprise determining whether tumor cells comprising one or more of the following characteristics:
[0188] (i) IRS-1 phosphorylation on tyrosine 896;
[0189] (ii) IRS-1 phosphorylation on tyrosine 612;
[0190] (iii) IRS-1 phosphorylation on any tyrosine;
[0191] (iv) IGF-II expression;
[0192] (v) IGF1R phosphorylation on any tyrosine; or
[0193] (vi) expression of IGF1R.
[0194] Tumor cells can be assayed to determine whether any of these characteristics are present by any of several methods commonly known in the art. In an embodiment, IRS-1 or IGF1R tyrosine phosphorylation can be determine by western blot analysis with an anti-phosphotyrosine antibody. For example, anti-phosphotyrosine antibodies PY20, PT66 and P-Try-100 are commercially available from PerkinElmer Life and Analytical Sciences, Inc. (Boston, Mass.); and anti-phosphotyrosine antibody 4G10 is commercially available from Upstate Cell Signaling Solutions (Waltham, Mass.). Western blot analysis is a conventional method that is well known in the art. In an embodiment, IRS-1 or IGF1R tyrosine phosphorylation can be determine by an Enzyme linked immunosorbent assay (ELISA) or immunoprecipitation. In an embodiment, expression of IGF1R or IGF-II by tumor cells can, similarly, be determined by western blot analysis, immunoprecipitation or by ELISA. Any of several anti-IGF1R antibodies known in the art, for example, as described herein, can be used.
[0195] Many references are available to provide guidance in applying the above techniques (Kohler et al., Hybridoma Techniques (Cold Spring Harbor Laboratory, New York, 1980); Tijssen, Practice and Theory of Enzyme Immunoassays (Elsevier, Amsterdam, 1985); Campbell, Monoclonal Antibody Technology (Elsevier, Amsterdam, 1984); Hurrell, Monoclonal Hybridoma Antibodies: Techniques and Applications (CRC Press, Boca Raton, Fla., 1982); Zola, Monoclonal Antibodies: A Manual of Techniques, pp. 147-158 (CRC Press, Inc., 1987)).
[0196] In an embodiment of the invention, IGF-II expression by a tumor cell can be determined by IGF-II RNA detection. In an embodiment of the invention, IGF-II RNA is determined by northern blot analysis. Northern blot analysis is a conventional technique well known in the art and is described, for example, in Molecular Cloning, a Laboratory Manual, second edition, 1989, Sambrook, Fritch, Maniatis, Cold Spring Harbor Press, 10 Skyline Drive, Plainview, N.Y. 11803-2500.

Dosage

[0197] In an embodiment, an IGF1R inhibitory agent is administered to a patient at a “therapeutically effective dosage” or “therapeutically effective amount” which preferably inhibits a disease or condition (e.g., tumor growth) to any extent—preferably by at least about 20%, more preferably by at least about 40%, even more preferably by at least about 60%, and still more preferably by at least about 80%-100% relative to untreated subjects. In an embodiment of the invention, the term “therapeutically effective amount” or “therapeutically effective dosage” means that amount or dosage of an IGF1R inhibitory agent (e.g., an anti-IGF1R antibody or antigen-binding fragment thereof) that will elicit a biological or medical response of a tissue, system, subject or host that is being sought by the administrator (such as a researcher, doctor or veterinarian) which includes any measurable alleviation of the signs, symptoms and/or clinical indicia of cancer (e.g., tumor growth) and/or the prevention, slowing or halting of progression or metastasis of cancer to any degree. The ability of an IGF1R inhibitory agent to inhibit cancer can be evaluated in an animal model system predictive of efficacy in human tumors. Alternatively, efficacy can be evaluated by examining the ability of a treatment of the invention or any component thereof to inhibit tumor cell growth in vitro by assays well-known to the skilled practitioner. One of ordinary skill in the art would be able to determine such amounts based on such factors as the subject's size, the severity of the subject's symptoms, and the particular composition or route of administration selected.
[0198] A clinician may use any of several methods known in the art to measure the effectiveness of a particular dosage scheme of an IGF1R inhibitory agent. For example, tumor size can be determined in a non-invasive route, such as by X-ray, positron emission tomography (PET) scan, computed tomography (CT) scan or magnetic resonance imaging (MRI).
[0199] A cancer or a tumor cell is “responsive” to an IGF1R inhibitory agent if the agent can provide any measurable alleviation of the signs, symptoms and/or clinical indicia of cancer (e.g., tumor growth) and/or the prevention, slowing or halting of progression or metastasis of cancer to any degree.
[0200] Dosage regimens may be adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a dose may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.
[0201] A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of an IGF1R inhibitory agent employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. The effectiveness of a given dose or treatment regimen of IGF1R inhibitory agent can be determined, for example, by determining whether a tumor being treated in the subject shrinks or ceases to grow.
[0202] In an embodiment of the invention, administration of IGF1R inhibitory agent is by injection proximal to the site of the target (e.g., tumor). In an embodiment, a therapeutically effective daily dose of IGF1R inhibitory agent or pharmaceutical composition thereof is administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day. In an embodiment, a “therapeutically effective” dosage of any anti-IGFR antibody (e.g., 19D12/15H12 LCF/HCA) is in the range of about 3 mg/kg (body weight) to about 20 mg/kg (e.g., 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, 10 mg/kg, 11 mg/kg, 12 mg/kg, 13 mg/kg, 14 mg/kg, 15 mg/kg, 16 mg/kg, 17 mg/kg, 18 mg/kg, 19 mg/kg or 20 mg/kg) per day. In an embodiment, a “therapeutically effective dosage” of a chemotherapeutic agent (e.g., an IGF1R inhibitory agent) is whenever possible as set forth in the Physicians' Desk Reference 2003 (Thomson Healthcare; 57th edition (Nov. 1, 2002)) which is herein incorporated by reference. For example, in an embodiment of the invention, a therapeutically effective dosage of NVP-ADW-742 is about 1 mg/kg/day to about 50 mg/kg/day (e.g., 5 mg/kg/day, 10 mg/kg/day, 15 mg/kg/day, 20 mg/kg/day, 25 mg/kg/day, 30 mg/kg/day, 35 mg/kg/day, 40 mg/kg/day, 45 mg/kg/day).

Therapeutic Methods and Administration

[0203] An IGF1R inhibitory agent can be used to inhibit or reduce the growth or proliferation of any cell, such as a malignant cell, either in vitro (e.g., in cell culture) or in vivo (e.g., within the body of a subject suffering from a disease mediated by elevated expression or activity of IGF1R or by elevated expression of its ligand (e.g., IGF-I or IGF-II)). Such inhibition or reduction of growth or proliferation of a cell can be achieved by contacting the cell with the IGF1R inhibitory agent.
[0204] In an embodiment, an IGF1R inhibitory agent is for treating cancer in a patient that is characterized by one or more of the following characteristics: IRS-1 phosphorylation on tyrosine 896; (ii) IRS-1 phosphorylation on tyrosine 612; (iii) IRS-1 phosphorylation on any tyrosine; (iv) IGF-II expression; (v) IGF1R phosphorylation on any tyrosine; or (vi) expression of IGF1R. For example, in an embodiment, the cancer is bladder cancer, Wilm's cancer, bone cancer, prostate cancer, lung cancer, endometrial cancer, multiple myeloma, non-small cell lung cancer (NSCLC), colon cancer, rectal cancer, colorectal cancer, breast cancer (estrogen receptor + or estrogen receptor ), cervical cancer, synovial sarcoma, ovarian cancer, pancreatic cancer, neuroblastoma, rhabdomyosarcoma, osteosarcoma, diarrhea associated with metastatic carcinoid or vasoactive intestinal peptide secreting tumor (e.g., VIPoma or Werner-Morrison syndrome).
[0205] In an embodiment, it is in initially determined if a prospective patient to be treated with an IGF1R inhibitory agent suffers from a variety of cancer that is commonly known to exhibit one of the following characteristics: (i) IRS-1 phosphorylation on tyrosine 896; (ii) IRS-1 phosphorylation on tyrosine 612; (iii) IRS-1 phosphorylation on any tyrosine; (iv) IGF-II expression; (v) IGF1R phosphorylation on any tyrosine; or (vi) expression of IGF1R. If the patient is determined to suffer from a cancer known to be characterized by one or more of the 6 characteristics set forth above, the patient is selected for treatment with an IGF1R inhibitory agent. A tumor type may be known to comprise any of the listed characteristics, for example, if such is established in scientific literature (e.g., periodic journals or textbooks) or if such is commonly known in the art by practitioners of ordinary skill or if such a characteristic has ever been observed in one or more patients or tumors, or if such can reasonably be inferred from experimental data (e.g., in vitro or in vivo data including animal data).
[0206] In an embodiment of the invention, a prospective patient's individual tumor is analyzed and it is determined whether the tumor exhibits one of more of the 6 characteristics: (i) IRS-1 phosphorylation on tyrosine 896; (ii) IRS-1 phosphorylation on tyrosine 612; (iii) IRS-1 phosphorylation on any tyrosine; (iv) IGF-II expression; (v) IGF1R phosphorylation on any tyrosine; or (vi) expression of IGF1R. In this embodiment, if the patient's tumor is determined to be characterized by one or more of the 6 characteristics set forth above, the patient is selected for treatment with an IGF1R inhibitory agent. In an embodiment, it is first determined whether the patient's tumor expresses the characteristic (i) IRS-1 phosphorylation on tyrosine 896 or (ii) IRS-1 phosphorylation on tyrosine 612; then, if such a characteristic is identified, it is determined whether the tumor comprises the characteristic (iv) IGF-II expression; if the patient's tumor is determined to express characteristic (i) or (ii) and characteristic (iv), then the patient is selected for treatment with an IGF1R inhibitory agent.
[0207] The cells from a particular patient's tumor can be obtained surgically, for example, by surgical biopsy. For example, a tumor biopsy can be taken by endoscopic biopsy, excisional or incisional biopsy or fine needle aspiration (FNA) biopsy.
[0208] The term “patient” or “subject” includes any organism, preferably an animal, more preferably a mammal (e.g., rat, mouse, dog, cat, rabbit) and most preferably a human.
[0209] As stated above, in an embodiment of the invention, where possible, an IGF1R inhibitory agent is administered to a subject in accordance with the Physicians' Desk Reference 2003 (Thomson Healthcare; 57th edition (Nov. 1, 2002)) or as set forth herein.
[0210] An IGF1R inhibitory agent can be administered by an invasive route such as by injection (see above). Administration by a non-invasive route (e.g., orally; for example, in a pill, capsule or tablet) is also within the scope of the present invention. In an embodiment of the invention, an anti-IGF1R antibody (e.g., 15H12/19D12 LCF/HCA), or pharmaceutical composition thereof, is administered intravenously, subcutaneously, intramuscularly, intraarterially or intratumorally.
[0211] An IGF1R inhibitory agent can be administered with medical devices known in the art. For example, a pharmaceutical composition of the invention can be administered by injection with a hypodermic needle.
[0212] The pharmaceutical compositions of the invention may also be administered with a needleless hypodermic injection device; such as the devices disclosed in U.S. Pat. No. 6,620,135; 6,096,002; 5,399,163; 5,383,851; 5,312,335; 5,064,413; 4,941,880; 4,790,824 or 4,596,556.
[0213] Examples of well-known implants and modules for administering pharmaceutical compositions include: U.S. Pat. No. 4,487,603, which discloses an implantable micro-infusion pump for dispensing medication at a controlled rate; U.S. Pat. No. 4,447,233, which discloses a medication infusion pump for delivering medication at a precise infusion rate; U.S. Pat. No. 4,447,224, which discloses a variable flow implantable infusion apparatus for continuous drug delivery; U.S. Pat. No. 4,439,196, which discloses an osmotic drug delivery system having multi-chamber compartments. Many other such implants, delivery systems, and modules are well known to those skilled in the art.

Pharmaceutical Compositions

[0214] An IGF1R inhibitory agent can be incorporated into a pharmaceutical composition, along with a pharmaceutically acceptable carrier, suitable for administration to a subject in vivo. The scope of the present invention includes pharmaceutical compositions which are suitable to be administered to a subject by any route including, for example, oral, ocular, topical, pulmonary (inhalation), intratumoral injection, intravenous injection, subcutaneous injection or intramuscular injection.
[0215] For general information concerning formulations, see, e.g., Gilman, et al., (eds.) (1990), The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pa.; Avis, et al., (eds.) (1993) Pharmaceutical Dosage Forms: Parenteral Medications Dekker, New York; Lieberman, et al., (eds.) (1990) Pharmaceutical Dosage Forms: Tablets Dekker, New York; and Lieberman, et al., (eds.) (1990), Pharmaceutical Dosage Forms: Disperse Systems Dekker, New York, Kenneth A. Walters (ed.) (2002) Dermatological and Transdermal Formulations (Drugs and the Pharmaceutical Sciences), Vol 119, Marcel Dekker.
[0216] Pharmaceutically acceptable carriers are conventional and very well known in the art. Examples include aqueous and nonaqueous carriers, stabilizers, antioxidants, solvents, dispersion media, coatings, antimicrobial agents, buffers, serum proteins, isotonic and absorption delaying agents, and the like that are physiologically compatible. Preferably, the carrier is suitable for injection into a subject's body.
[0217] Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
[0218] Examples of pharmaceutically-acceptable antioxidants include: water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; and oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
[0219] Prevention of the presence of microorganisms may be ensured both by sterilization procedures, and by the inclusion of various antimicrobial agents such as EDTA, EGTA, paraben, chlorobutanol, phenol sorbic acid, and the like.
[0220] Suitable buffers which may be included in the pharmaceutical compositions of the invention include L-histidine based buffers, phosphate based buffers (e.g., phosphate buffered saline, pH≅7), sorbate based buffers or glycine-based buffers.
[0221] Serum proteins which may be included in the pharmaceutical compositions of the invention may include human serum albumin.
[0222] Isotonic agents, such as sugars (e.g., sucrose), ethanol, polyalcohols (e.g., glycerol, propylene glycol, liquid polyethylene glycol, mannitol or sorbitol), sodium citrate or sodium chloride (e.g., buffered saline) may also be included in the pharmaceutical compositions of the invention. In an embodiment of the invention, the sugar, for example, glucose or sucrose is present at a high concentration (e.g., about 10-100 mg/ml, e.g., 50 mg/ml, 60 mg/ml or 70 mg/ml).
[0223] Prolonged absorption of an injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and/or gelatin.
[0224] Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils.
[0225] Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The use of such media and agents for pharmaceutically active substances is well known in the art.
[0226] Sterile injectable solutions comprising an anti-IGF1R antibody can be prepared by incorporating the antibody or antigen-binding fragment thereof in the required amount in an appropriate solvent, optionally with one or a combination of ingredients enumerated above, as required, followed by sterilization microfiltration. Generally, dispersions are prepared by incorporating the antibody into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying (lyophilization) that yield a powder of the active ingredient plus any additional, desired ingredient from a previously sterile-filtered solution thereof.
[0227] In an embodiment of the invention, an anti-IGF1R antibody of the invention is in a pharmaceutical formulation comprising a therapeutically effective amount of said antibody, a buffer and sucrose. For example, in an embodiment of the invention, the buffer is any one of phosphate buffer, citrate buffer, histidine buffer, glycine buffer or acetate buffer. The pharmaceutical formulation can be within any suitable pH range. In an embodiment of the invention, the pH is 5.0, 5.5, 6.0, 7.5, or between about 5.5 and about 6 or between about 5 and about 7.
[0228] An IGF1R inhibitory agent including an anti-IGF1R antibody or antigen-binding fragment thereof can be orally administered. Pharmaceutical compositions for oral administration may contain, in addition to the binding composition, additives such as starch (e.g., potato, maize or wheat starch or cellulose), starch derivatives (e.g., microcrystalline cellulose or silica), sugars (e.g., lactose), talc, stearate, magnesium carbonate or calcium phosphate. In order to ensure that oral compositions comprising an antibody or antigen-binding fragment of the invention are well tolerated by the patient's digestive system, mucus formers or resins may be included. It may also be desirable to improve tolerance by formulating the antibody or antigen-binding fragment in a capsule which is insoluble in the gastric juices. An exemplary pharmaceutical composition of this invention in the form of a capsule is prepared by filling a standard two-piece hard gelatin capsule with the antibody or antigen-binding fragment of the invention in powdered form, lactose, talc and magnesium stearate. Oral administration of immunoglobulins has been described (Foster, et al., (2001) Cochrane Database System rev. 3:CD001816)
[0229] An IGF1R inhibitory agent may also be included in a pharmaceutical composition for topical administration. Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site where treatment is required, such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.
[0230] Drops may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving an IGF1R inhibitory agent in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent. The resulting solution may then be clarified by filtration.
[0231] Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile, aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
[0232] Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing an IGF1R inhibitory agent in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy basis. The basis may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives, or a fatty acid such as stearic or oleic acid together with an alcohol such as propylene glycol or macrogels. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surface active such as sorbitan esters or polyoxyethylene derivatives thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
[0233] An IGF1R inhibitory agent may also be administered by inhalation. A suitable pharmaceutical composition for inhalation may be an aerosol. An exemplary pharmaceutical composition for inhalation of an antibody or antigen-binding fragment of the invention may include: an aerosol container with a capacity of 15-20 ml comprising the antibody or antigen-binding fragment of the invention, a lubricating agent, such as polysorbate 85 or oleic acid, dispersed in a propellant, such as freon, preferably in a combination of 1,2-dichlorotetrafluoroethane and difluorochloromethane. Preferably, the composition is in an appropriate aerosol container adapted for either intranasal or oral inhalation administration.

Kits and Articles of Manufacture

[0234] Kits and articles of manufacture of the present invention include an IGF1R inhibitory agent, preferably combined with a pharmaceutically acceptable carrier, in a pharmaceutical formulation, more preferably in a pharmaceutical dosage form such as a pill, a powder, an injectable liquid, a tablet, dispersible granules, a capsule, a cachet or a suppository. See for example, Gilman et al. (eds.) (1990), The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, supra, Easton, Pa.; Avis et al. (eds.) (1993) Pharmaceutical Dosage Forms: Parenteral Medications Dekker, New York; Lieberman et al. (eds.) (1990) Pharmaceutical Dosage Forms: Tablets Dekker, New York; and Lieberman et al. (eds.) (1990), Pharmaceutical Dosage Forms: Disperse Systems Dekker, New York.
[0235] The kits and articles of manufacture of the present invention also include information, for example in the form of a package insert or label, indicating that the target of the IGF1R inhibitory agent is IGF1R. The term “target” indicates that the agent reduces or inhibits ligand binding, kinase activity, expression or any other biological activity of IGF1R in any way. The insert or label may take any form, such as paper or on electronic media such as a magnetically recorded medium (e.g., floppy disk) or a CD-ROM.
[0236] The label or insert may also include other information concerning the pharmaceutical compositions and dosage forms in the kit or article of manufacture. Generally, such information aids patients and physicians in using the enclosed pharmaceutical compositions and dosage forms effectively and safely. For example, the following information regarding the IGF1R inhibitory agent may be supplied in the insert: pharmacokinetics, pharmacodynamics, clinical studies, efficacy parameters, indications and usage, contraindications, warnings, precautions, adverse reactions, overdosage, proper dosage and administration, how supplied, proper storage conditions, references and patent information.

EXAMPLES

[0237] This section is intended to further describe the present invention and should not be construed to further limit the invention. Any composition or method set forth herein comprises part of the present invention.
[0238] In this example, the level of phosphorylation of IRS-1 in human lung tumor tissue was compared to that of normal tissue samples and found to be higher in tumor cells than in normal cells. Also, the in vivo efficacy of the anti-IGF1R antibody 19D12/15H12 LCF/HCA was correlated with the ability of the IGF-1 to cause IRS-1 phosphorylation. In addition, the level of IGF-II mRNA expression was evaluated in 56 different normal and cancerous ovarian and colorectal tissue samples and found to be high in several samples of tumor tissue.
[0239] Tumor lysate preparation. Tumor tissues were first weighed and pulverized into fine powder with a pre-chilled pulverizer on dry ice. Tumor powders were transferred into a tube, and 4.5× volume of the buffer A (i.e., 450 ul buffer A per 100 mg tissue) was added. The samples were sonicated for 30 seconds, 0.5× volume of buffer B (i.e., add 50 ul buffer B per 100 mg tissue powder) was added, and samples were spun for 13,000 rpm for 20 min at 4° C. after incubation on ice for 30 min. Supernatants were collected and protein concentrations of the lysates were determined by Bio-Rad assay.
[0240] Buffer A: 50 mM Hepes, pH 7.4, 150 mM NaCl, 5% Glycerol, 1.5 mM MgCl2, 2 mM Sodium Vanadate, 5 mM NaF, Protease inhibitors (2× concentrated C complete EDTA-free from Roche-cat #. 1 873 580), Phosphatase inhibitor Cocktail 1 (Sigma p2850), Phosphatase inhibitor Cocktail 2 (Sigma p5726).
Buffer B: Buffer A plus 10% Triton-100
[0241] Cell culture lysate preparation. Cells were washed in PBS once, lysed in buffer containing 50 mM Hepes, pH7.4, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl2, 2 mM Na3VO4 and protease inhibitor cocktail (Complete™, Roche Diagnostics GmbH; Mannheim, Germany). Samples were spun for 13,000 rpm for 10 min at 4° C. after incubation on ice for 30 min. Supernatants were collected and protein concentrations of the lysates were determined by Bio-Rad assay.
[0242] Western analysis. Equal amounts of cell or tumor lysates were separated on a SDS-PAGE, transferred to nitrocellulose filters, probed with desired antibodies, and visualized by ECL (Amersham; Piscataway, N.J.). Antibodies for detecting IGFR and IRS-1 were from Santa Cruz Biotechnology (Santa Cruz, Calif.). Antibodies against phospho-IRS1[pY896] and phospho-IRS1[pY612] were from Biosource (Camarillo, Calif.).
[0243] IGF-II protein measurement. Cells from various cell lines were seeded in T-175 plates in medium containing 10% FBS. After cells were attached, medium was changed to serum free medium. Medium was collected, all debris was spun down, and the supernatants were lyophilized. Cells on the plates were trypsinized and counted. Water was added to each lyophilized supernatant sample (1 ml/2×107 cells). IGF-II was measured using the IGF-II ELISA kit from DSL (DSL-10-2600). IGF-II amounts were determined by the standard curve and reported as nanogram IGF-II per 1×106 cells.
[0244] IGF-II mRNA measurement. RNAs were made from tumor samples and cDNAs were synthesized. Expression of IGF-II was analyzed on 20 ng of cDNA sample in a Fluorogenic 5′-nuclease PCR assay with specific probes and primers using the ABI Prism 7700 Sequence Detection System (Applied Biosystems; Foster City, Calif.). CT numbers were normalized by determining Ubiquitin (reference gene) mRNA expression in all samples.
[0245] 
[00029] [TABLE-US-00029]
    IGF2/forward:    
    AGGAGCTCGAGGCGTTCAG   (SEQ ID NO: 102)
   
    IGF2/reverse:
    GTCTTGGGTGGGTAGAGCAATC   (SEQ ID NO: 103)
   
    probe:
    AGGCCAAACGTCACCGTCCCC   (SEQ ID NO: 104)
[0246] Xenograft models in mice. Four to five million human tumor cells (H322, H838, A2780, ES2, MCF7, SW-527, SK-N-AS, SK-N-MC) in Matrigel were inoculated subcutaneously into each nude mouse. When the tumor size reached at least ˜50 mm3, 19D12/15H12 LCF/HCA treatment was initiated and continued with dosing two times per week. 19D12/15H12 LCF/HCA was injected into each nude mouse, intraperitoneally, at 0.004 mg/mouse, 0.02 mg/mouse, 0.1 mg/mouse or 0.5 mg/mouse. Tumor volumes were measured by Labcat.
[0247] IRS-1 phosphorylation level in human lung cancer and normal tissue samples. Twelve pairs of samples of normal and cancerous human lung cancerous tissue samples were obtained from patients. Cell lysates were prepared from the tissue samples and subjected to western blot analysis, staining with anti-phospho-IRS1[pY896] as described above. Total IRS-1 was also measured by staining with an anti-IRS antibody.
[0248] The western blot data generated in these experiments is set forth in FIG. 1. In 6 out of the 12 sample pairs evaluated (50%), greater phospho-IRS-1 levels were observed in tumor tissue samples than in the corresponding normal tissue sample.
[0249] Similar results were observed when the level of IRS-1 phosphorylation was measured in normal and cancerous colorectal tissue samples. The colorectal tissue samples were evaluated essentially identically to that way the lung tissue samples were evaluated.
[0250] Correlation of In vivo efficacy of 19D12/15H12 LCF/HCA with IRS-1 phosphorylation. To evaluate in vivo efficacy of 19D12/15H12 LCF/HCA antibody, nude mice bearing human tumor xenografts were administered the antibody or an isotype control, and tumor volume was evaluated over time as described above.
[0251] To evaluate IRS-1 phosphorylation in tumor cell lines, cell lines were grown in the presence of absence of 100 ng/ml IGF-I. Cell lysates of A2780, ES2, H322, H838 and SK-N-AS cells were then prepared and evaluate-d by western blot analysis as describe above.
[0252] The results of the in vivo efficacy experiments are set forth in FIG. 2. The 19D12/15H12 LCF/HCA antibody was found to be effective at inhibiting the growth of several types of tumors in vivo (e.g., non-small cell lung cancer, ovarian cancer, breast cancer, neuroblastoma).
[0253] The results of the experiments measuring basal and IGF-I stimulated IRS-1 phosphorylation in tumor cells are set forth in FIG. 3. The A2780, H322 and SK-N-AS cell lines evaluated exhibited the greatest basal and IGF-I stimulated IRS-1 phosphorylation.
[0254] The cell lines that were most sensitive, in vivo, to growth inhibition by 19D12/15H12 LCF/HCA (FIG. 2) were those that showed the greatest basal and IGF-I stimulated IRS-1 phosphorylation (FIG. 3).
[0255] IGF-II mRNA expression level in ovarian and colorectal tumor samples. Normal and cancerous ovarian and colorectal tissue samples were obtained from multiple cancer patients. The level of IGF-II mRNA expression was evaluated, by Taqman analysis, as described above. The level of IGF-II mRNA expression of each ovarian tissue sample is set forth in FIG. 4 and the level of IGF-II mRNA expression in each colorectal tissue sample is set forth in FIG. 5. In these experiments, 20% of ovarian tumor samples were found to overexpress IGF-II mRNA as compared to normal ovarian tissue samples. Fifty three percent of colorectal samples were found to overexpress IGF-II mRNA as compared with adjacent, normal colorectal samples.
[0256] The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
[0257] Patents, patent applications, Genbank Accession Numbers and publications are cited throughout this application, the disclosures of which are incorporated herein by reference in their entireties.
(57)

Claims

1. A method for treating a non-small cell lung tumor, an ovarian tumor, a neuroblastoma tumor or an osteosarcoma tumor in a mammalian patient wherein growth or survival of the tumor is mediated by IGF1R expression or activity said method comprising:
(a) selecting a mammalian patient having a non-small cell lung tumor, an ovarian tumor, a neuroblastoma tumor or an osteosarcoma tumor expressing phosphorylated IRS-1 tyrosine 896 or phosphorylated IRS-1 tyrosine 612; and
(b) administering to said mammalian patient a therapeutically effective amount of an isolated antibody that binds specifically to IGF1R comprising a light chain immunoglobulin variable domain comprising the amino acid sequence: EIVLTQSPGT LSVSPGERATLSCRASQSIGSSLHWYQQKPGQAPRLLIKYASQSLSGIPD RFSGSGSGTDFTLTISRLEPEDFAVYYCHQSSRLPHTFGQGTKVEIKRT (amino acids 20-128 of SEQ ID NO: 8); and a heavy chain immunoglobulin variable domain comprising the amino acid sequence: EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWISVIDTRGATYYA DSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGNFYYGMDVWGQGTTVTVSS (amino acids 20-137 of SEQ ID NO: 10); wherein said antibody inhibits growth or survival of said tumor.
2. The method of claim 1 wherein the tumor is an osteosarcoma tumor.
3. The method of claim 2 wherein the antibody is a monoclonal antibody and the patient is a human.
4. The method of claim 2 wherein the antibody is a fully human monoclonal antibody and the patient is a human.
5. The method of claim 3 wherein said light chain immunoglobulin variable domain is conjugated to an immunoglobulin kappa constant domain and said heavy chain immunoglobulin variable domain is conjugated to an immunoglobulin gamma 1 constant domain.
6. The method of claim 4 wherein said light chain immunoglobulin variable domain is conjugated to an immunoglobulin kappa constant domain and said heavy chain immunoglobulin variable domain is conjugated to an immunoglobulin gamma 1 constant domain.
7. The method of claim 3 wherein said patient is administered the monoclonal antibody in association with one or more additional anti-cancer agents.
8. The method of claim 7 wherein the patient is administered said monoclonal antibody in association with one or more additional anti-cancer agents selected from the group consisting of: paclitaxel, thalidomide, docetaxel, gefitinib, temozolomide, lonafarnib, tipifarnib, letrozole, doxorubicin, cis-platin, oxaliplatin, camptothecin, topotecan, etoposide, vincristine, vinblastine, raloxifene, gemcitabine, retinoic acid, tamoxifen, trastuzumab, cetuximab and octreotide.
9. The method of claim 4 wherein said patient is administered the monoclonal antibody in association with one or more additional anti-cancer agents.
10. The method of claim 9 wherein the patient is administered said monoclonal antibody in association with one or more additional anti-cancer agents selected from the group consisting of: paclitaxel, thalidomide, docetaxel, gefitinib, temozolomide, lonafarnib, tipifarnib, letrozole, doxorubicin, cis-platin, oxaliplatin, camptothecin, topotecan, etoposide, vincristine, vinblastine, raloxifene, gemcitabine, retinoic acid, tamoxifen, trastuzumab, cetuximab and octreotide.
11. The method of claim 8 wherein the additional anti-cancer agent is paclitaxel.
12. The method of claim 8 wherein the additional anti-cancer agent is docetaxel.
13. The method of claim 8 wherein the additional anti-cancer agent is gefitinib.
14. The method of claim 8 wherein the additional anti-cancer agent is cis-platin.
15. The method of claim 8 wherein the additional anti-cancer agent is oxaliplatin.
16. The method of claim 8 wherein the additional anti-cancer agent is octreotide.
*****

Download Citation


Sign in to the Lens

Feedback